SEARCH

SEARCH BY CITATION

Keywords:

  • interstitial cystitis;
  • bladder hypersensitivity;
  • guideline

Abstract

  1. Top of page
  2. Abstract
  3. Introduction
  4. Methods
  5. Definition
  6. Etiology and pathogenesis
  7. Epidemiology
  8. Quality of life
  9. Diagnosis
  10. Treatment
  11. Assessment of therapeutic effectiveness
  12. Clinical algorithm
  13. References

A clinical guideline and algorism for interstitial cystitis and hypersensitive bladder syndrome has been developed by a group of East Asian urologists as a revised form of the Japanese guideline for interstitial cystitis. The guideline defines interstitial cystitis (IC) as a disease of the urinary bladder diagnosed by 3 requirements; 1) a characteristic complex of lower urinary tract symptoms, 2) bladder pathology such as Hunner's ulcer and bladder bleeding after overdistension, and 3) exclusions of confusable diseases. The characteristic symptom complex is termed as hypersensitive bladder syndrome (HBS), which is defined as bladder hypersensitivity, usually associated with urinary frequency, with or without bladder pain. For the definite diagnosis of IC, cytoscopy or hydrodistension is crutial; HBS is the diagnosis when IC is suspected but not confirmed by the 3 requirements. Numerous therapeutic options are available; however, most of them lack in high level of evidence, leaving a few as recommended therapies. Etiology of IC are multifactorial; the interaction among nervous, immune and endocrine factors forms a vicious cycle, provocating and maintaining inflammatory reactions in the bladder. The inclusion and efficacy criteria for clinical trials should be standardized to enhance the clinical research for this disabling disease, which has proved to be more prevalent than previously believed.


Introduction

  1. Top of page
  2. Abstract
  3. Introduction
  4. Methods
  5. Definition
  6. Etiology and pathogenesis
  7. Epidemiology
  8. Quality of life
  9. Diagnosis
  10. Treatment
  11. Assessment of therapeutic effectiveness
  12. Clinical algorithm
  13. References

Interstitial cystitis (IC) is a disease of the urinary bladder with lower urinary tract symptoms such as bladder hypersensitivity, urinary frequency, and bladder pain and resulting in serious impairment of quality of life. In Asia the research and medical care of IC has been sparse because of an assumption that IC is very rare. In recent years, the realization that IC is a common disease in Asia has lead to an increase in academic and social activities regarding IC. However, the etiology of IC has not yet been clarified, which introduces confusion to the disease definition, and complicates its diagnosis and treatment. Thus the present article is an attempt to develop a clinical guideline, which is targeted at healthcare professionals including specialists in urology and women's health care who may engage in the diagnosis and treatment of IC and IC-related conditions.

Methods

  1. Top of page
  2. Abstract
  3. Introduction
  4. Methods
  5. Definition
  6. Etiology and pathogenesis
  7. Epidemiology
  8. Quality of life
  9. Diagnosis
  10. Treatment
  11. Assessment of therapeutic effectiveness
  12. Clinical algorithm
  13. References

The Japanese IC guideline, which was written by SICJ members in 2006 and endorsed by the Japanese Urological Association1,2 was used as the basis. For the Japanese guideline 1350 articles searched by the PubMed database in 2005 with the keyword, ‘interstitial cystitis’, were surveyed. For the present guideline, the articles published from 2006 to 2008 were additionally surveyed. Other sources of references included the reports of the International Consultation of Interstitial Cystitis in Japan (ICICJ),3,4 International Consultation on Incontinence (ICI) report,5 and the Guideline for Chronic Pelvic Pain by the European Association of Urology.6 The members met three times for discussion.

Definition

  1. Top of page
  2. Abstract
  3. Introduction
  4. Methods
  5. Definition
  6. Etiology and pathogenesis
  7. Epidemiology
  8. Quality of life
  9. Diagnosis
  10. Treatment
  11. Assessment of therapeutic effectiveness
  12. Clinical algorithm
  13. References

We define interstitial cystitis as a disease of the urinary bladder diagnosed by three conditions; lower urinary tract symptoms, bladder pathology and exclusions of confusable diseases. The characteristic symptom complex is termed as hypersensitive bladder syndrome (HBS), which is defined as bladder hypersensitivity, usually associated with urinary frequency, with or without bladder pain.

Despite its long history7 there is no widely accepted definition of IC.8,9 The National Institute of Diabetes and Digestive Kidney Diseases (NIDDK) consensus criteria, which were developed to ensure the comparability of patients enrolled in clinical studies,10 would be too restrictive for clinical diagnosis.11

Due to its unclear definition, many terms that refer to IC or IC-related conditions have been used:12 interstitial cystitis (IC), painful bladder syndrome (PBS), chronic pelvic pain syndrome (CPPS), IC/PBS (PBS/IC), IC/CPPS (CPPS/IC) and bladder pain syndrome (BPS) are examples. IC has been used since the nineteenth century and is most universally recognized as a disease entity in academic, medico-legal or medico-economical societies. Meanwhile IC intuitively indicates inflammation in the interstitum, which is not necessarily true histopathologically.13 PBS has been used in various meanings since the 1980s,14 and was defined in 2002 as the complaint of suprapubic pain related to bladder filling, accompanied by other symptoms such as frequency and nocturia in the absence of proven pathologies.15 PBS is recognized as an umbrella term with IC as a sub-type, which implicates that PBS includes IC.16 CPPS refers to a symptom syndrome with chronic pelvic pain15 resulting from a variety of diseases including IC.17 BPS is also a pain syndrome proposed by the European Society for the Study of IC/PBS (ESSIC) to replace the term IC.18 Chronic pain syndromes would be appropriate for IC or IC-related conditions,8 because bladder and/or pelvic pains are characteristic to those conditions,16 and they show substantial clinical overlap with other pain syndromes like fibromyalgia.19 Unfortunately these terms would be inappropriate somehow; IC or IC-related conditions show high diversity in symptoms, and a significant proportion of IC patients do not complain of pain but relate their feelings to pressure and discomfort.20 According to the definition by the International Association for the Study of Pain,21 pain is ‘an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage’, thus includes pressure or discomfort as a kind of pain. However, it would be unrealistic for common physicians and patients to use ‘pain’ to describe pressure or discomfort in accord with the scientific definition. Patients not complaining of pain would remain undiagnosed for IC, if only pain syndromes are applicable to IC or IC-related conditions.14,22 The term ‘IC/PBS’ inclusively covers diverse patient populations from those meeting NIDDK criteria to those only having bladder pain. However, this double-barreled term is a chimera combining a disease name and a symptom syndrome name, and is thus linguistically inappropriate and misleading.

In the present guideline, we have defined IC as ‘a disease of the urinary bladder diagnosed by three conditions: (i) lower urinary tract symptoms such as bladder hypersensitivity, urinary frequency, bladder discomfort and bladder pain; (ii) bladder pathology such as Hunner's ulcer and mucosal bleeding after over-distension; and (iii) exclusions of confusable diseases such as infection, malignancy and calculi of the urinary tract.2 For the symptoms, we propose a new symptom syndrome, ‘hypersensitive bladder syndrome (HBS)’.23 HBS could be defined as bladder hypersensitivity, usually associated with urinary frequency, with or without bladder pain if it should appear like the definition of overactive bladder syndrome (urinary urgency, usually associated with urinary frequency, with or without urgency incontinence). Increased bladder sensation is defined as the early and persistent desire to void.15 Hypersensitive bladder was once used as a term for idiopathic sensory urgency and ‘early’ IC,24 and recently it has been implicated with overexpression of TRPV1 mRNA,25 responsiveness to intravesical Resiniferatoxin26 or possible overlapping with overactive bladder syndrome.27 Thus HBS would be a clinical entity that is more inclusive than pain syndromes: it incorporates patients complaining and not complaining of pain.23 HBS can be used as a descriptive term for symptom complex, or as a diagnostic name for the condition that is suspected of IC but has not fulfilled all of the requirements for IC diagnosis. For the bladder pathology, bladder bleeding after overdistension may not be highly sensitive28 or specific,29,30 although it would be the sole abnormal endoscopic finding when Hunner's ulcer is absent.

Etiology and pathogenesis

  1. Top of page
  2. Abstract
  3. Introduction
  4. Methods
  5. Definition
  6. Etiology and pathogenesis
  7. Epidemiology
  8. Quality of life
  9. Diagnosis
  10. Treatment
  11. Assessment of therapeutic effectiveness
  12. Clinical algorithm
  13. References

Etiology of interstitial cystitis would be multifactorial. The interaction among nervous, immune and endocrine factors forms a vicious cycle, provoking and maintaining inflammatory reactions in the bladder.

Defective or dysfunctional bladder epithelium

The glycosaminoglycan (GAG) layer protects the bladder mucosa as a chemical barrier against urine. If it is defective, infiltrated urine would induce submucosal inflammation, stimulating sensory nerve fibers and causing frequency and pain.31 However, the reason why the GAG layer becomes defective has been unknown. Anti-proliferative factors (APF), detected in the urine of IC patients, downregulate gene expressions that stimulate proliferation of bladder epithelial cells and upregulate genes that inhibit proliferation, leading to urothelial under-maturation and dysfunctions.32,33 The factor increased the paracellular permeability,34 and can be potentially a specific diagnostic biomarker for IC. Aberrant epithelial expression of functional proteins such as E-cadherin, chondroitin sulfate, perlecan, biglycan, decorin, ZO-1, uroplakin, keratin and syndecan-1 can partially explain dysfunctional bladder epithelium.35–38 Upregulation of TRPV1,25 increased the release of adenosine 5′-triphosphate (ATP)39 or decreased production of PGE2 from the urothelium40 may play a role in pathogenesis of hypersensitivity or inflammation. However, few differences in gene expression were found in cultured keratinocyte of IC patients.41

Mast cell activation and/or inflammation

Mast cells are a central player in the inflammatory process: they release potent inflammatory mediators such as histamine, leukotriene and serotonin, and also interact with immunoglobulin E (IgE) antibodies, other inflammatory cells and nervous systems.42,43 The mast cell count is increased in the bladder tissue from IC, but the increase is not specific to IC and unclear in non-ulcer type IC.42,44,45 Inflammatory mediators including nitric oxide are concentrated in the affected bladder tissue,46,47 and interact with each other to enhance the activities; that is, leukotriene D4 potentiates histamine-induced increase in the intracellular calcium concentration.48 Blockade of interferon-gamma-inducible protein-10 (CXCL10), a potent inflammatory chemokine, inhibited cyclophosphamide-induced cystitis in mice.49

Infection

Infection of microorganism has never been identified as the direct cause of IC.50 No study has proven overproduction of urinary IgA and IgG,51 presence of bacterial 16SrRNA genes by PCR,52 or viral genes.53 It is widely recognized that antibiotic treatment is ineffective for IC. As the symptoms flare, mechanisms other than infection should be considered as the trigger.54 Yet, infection is occasionally an associated factor to initiate or worsen IC.55

Urinary toxic agents

Toxic agents in the urine, for example, potassium ion, may distort epithelial function of the urinary bladder and cause symptoms. Urine is necessary to provoke bladder inflammation induced by protamine injection.56 One hypothesis is that heat labile cationic urine components of low molecular weight exert toxic effects to bladder mucosa.57 IC-like symptoms by chronic ketamine abuse may be related to the toxic effects of ketamine and its metabolites.58 Urinary pH alone is unlikely to pronounce pain symptoms.59

Hypoxia

A decrease in the microvascular density in the submucosal layer is found in IC.60 Bladder vascular perfusion is reduced by bladder filling in IC, while it is rather increased in controls.61 Hyperbaric therapy is known to relieve IC symptoms. It is conceivable that the impaired blood circulation in the bladder is related to IC. In the affected bladder apoptotic activity of microvascular endothelial cells was increased.62

Impaired pelvic health

Women with IC have often the history of hysterectomy, cesarean births, miscarriage, stillbirth or abortion.63,64 Pelvic surgeries can be the trigger of the symptom development. The symptoms are likely to be affected by menstruation cycle.63 Both IC symptoms and irritable bowel syndrome were improved by treating small-intestinal bacterial overgrowth, which allegedly potentiates visceral hypersensitivity.65

Immunity and allergy

A number of reports suggest the existence of auto-antibodies in IC patients.66–69 The primary antibody detected in IC is anti-nuclear antibody, which is similar in auto-antibody profile to systemic autoimmune diseases such as Sjogren's syndrome.70 Mice immunized by bladder homogenate develop autoimmune cystitis comparable to IC.71 Increase of specific IgE is implicated with pathogenesis in a subset of IC patients.72 Reduced estrogen receptor β signaling may have a role in the pathogenesis through hyperactivation of T cells and autoimmune destruction of urothelium.73 However, the specific auto-antibody has not been identified in IC.

Neurogenic inflammation

Abnormality in the nervous system is an important potential etiology of IC. Nervous system is affected in IC patients;74–76 for example, predominance of the sympathetic nervous system,77 increased tyrosine hydroxylase, activation of purinergic nerves, and decreased expression of the S-100 family in Schwann cells.78–81 Ultrastructural histopathology showed characteristic features of neurogenic inflammation in IC.82 Inculcation of pseudorabies virus in the abductor caudalis dorsalis resulted in cystitis with mast cells accumulated in the mouse bladder wall.83

Emotion and autonomic nervous system

Interstitial cystitis is associated with increased sympathetic tone along with decreased cortisol level.84,85 Multiple diagnoses with other ill-defined diseases including irritable bowel syndrome, pelvic floor tension myalgia, abdominal wall myalgia, and vulvodynia are common,84,86 and a history of abuse or depressed psychological profiles were identified.87–92 Patients with a sexual abuse history are likely to present more pain and fewer voiding problems.93 Stress reduction is therapeutically beneficial for the symptom relief.94 These facts suggest interaction between the development of IC symptoms and central sensitization to mental stress.

Interaction among pathogenic factors

No single factor of the above mentioned etiologies alone could explain the entire process of IC pathogenesis; the etiology of IC is a complex interaction among nervous, immune, and endocrine systems.95 For example, mast cell activation by adjacent nerve endings can be affected by estradiol and corticotrophin-releasing hormone (CRH).96 Urinary levels of tryptase, nerve growth factor, neurotrophin-3 and glial cell line-derived neurotrophic factor increased in IC.97 The co-expression of stem cell factor and interleukin-6 (IL-6) is implicated with epithelial migration of mast cells.42 A nuclear factor-kappa β subunit was overproduced and the expression of IL-6 gene increased five times after activation of NF-kappa β in IC.98 Neural upregulation, both peripheral and central, is presumed to maintain the chronicity of symptoms,99,100 and cross talk in pelvic organs suggests a mechanism by which bowel or uterine pathology modulates the IC symptoms.101 A hypothetical pathway would be that the events such as injured urothelium and/or reduced oxygen tension initiate inflammatory reactions including overproduction and/or under-degradation of cytokines and growth factors, infiltration of immunocompetent cells such as mast cells and upregulation of sensory nerves, forming a vicious cycle to enhance inflammation in the bladder interstitum. In this regard, IC is a neuro-immuno-endocrine disorder or an ‘over healing’ disorder of the urinary bladder.46

Epidemiology

  1. Top of page
  2. Abstract
  3. Introduction
  4. Methods
  5. Definition
  6. Etiology and pathogenesis
  7. Epidemiology
  8. Quality of life
  9. Diagnosis
  10. Treatment
  11. Assessment of therapeutic effectiveness
  12. Clinical algorithm
  13. References

Recent studies uniformly indicate a higher prevalence of interstitial cystitis (including suspected) than previously believed, roughly one percent.

In Finland, the prevalence was estimated at 10.1 cases per 100 000 (0.01%) in 1975 based on positive symptoms, negative urinary tract infection and positive bladder biopsy.102 Following studies in 2002 indicated it as 450 per 100 000 (0.45%), and more recently it was 680 per 100 000 (0.68%) for a probable IC and 300 per 100 000 (0.3%) for a definite diagnosis of IC.103,104 The prevalence of 306 per 100 000 (0.3%) was reported in 2007 in Austria.105 In the United States, a questionnaire survey in 1987 indicated at least 43 500 IC patients and 217 500 possibly IC patients (0.014% and 0.07%, respectively). A report in 1994 suggested a prevalence of 0.5% of the total population.106 A survey with female nurses in 1999 estimated 52 to 67 per 100 000 (0.05 to 0.06%).107 A study using the managed care database showed 197 female and 41 male patients with IC per 100 000 (0.19% and 0.04%), respectively.108 The recent study indicates prevalences of IC symptoms of 1.3% in men and 2.3% in women.64 No evident racial/ethnic disparity or limited gender disparity exists in the prevalence of symptoms.89,109

In Japan, the prevalence was reported in 1998 to be only 2 per 100 000 patients by a questionnaire survey of 300 major hospitals.110 Japanese patients tended to be older (52.9 years in average) than those in Europe and the United States.111 This may indicate that Japanese patients have had symptoms for a long time before diagnosis. However, a recent epidemiological investigation in Japan found that 1.0% of the general population experienced bladder pain every day.112 In Korea, the results of the PUF questionnaire indicated a much higher prevalence (6.2%) of possible IC in women. In Taiwan, a study inquiring 1271 female adults aged 30 years and older by the O'Leary-Sant symptom/problem score disclosed that 0.31% of the surveyed women had a probable IC.

Known risk factors include smoking, depression, generalized pain disorders, irritable bowel syndrome, hysterectomy, and urinary tract infection.64,87,113 The economic burden is estimated to be substantial in the United States.114,115 Because of misdiagnosis, the true burden of IC on the health care system in the United States is probably underestimated.

Quality of life

  1. Top of page
  2. Abstract
  3. Introduction
  4. Methods
  5. Definition
  6. Etiology and pathogenesis
  7. Epidemiology
  8. Quality of life
  9. Diagnosis
  10. Treatment
  11. Assessment of therapeutic effectiveness
  12. Clinical algorithm
  13. References

Interstitial cystitis is a disease which profoundly affects patients' quality of life due to disabling symptoms.

A study evaluated quality of life (QOL) in 424 patients by Short Form 36 (SF-36),116 reporting that about 80% of the patients felt adverse affects of IC on daily living and social lives. Two subsequent studies confirmed that IC patients had significantly worse QOL by SF36 scores in many aspects compared with age-matched women without IC.117,118 A Japanese study found severely impaired QOL in IC patients by SF-36 and the King's Health Questionnaire (KHQ) scales.119 It is even worse when compared with the patients with chronic renal failure requiring hemodialysis, Crohn's disease, systemic lupus erythematosus or rheumatoid arthritis. Most patients feature significant depression and anxiety.90 Impairment in mental health dimension was demonstrated by specific scales for depression.118 Sexual functioning, employment and pain issues predict mental and physical domains in women with long-standing symptoms.120–123

Diagnosis

  1. Top of page
  2. Abstract
  3. Introduction
  4. Methods
  5. Definition
  6. Etiology and pathogenesis
  7. Epidemiology
  8. Quality of life
  9. Diagnosis
  10. Treatment
  11. Assessment of therapeutic effectiveness
  12. Clinical algorithm
  13. References

Interstitial cystitis is diagnosed by three requirements: symptoms (hypersensitivity, urinary frequency, bladder discomfort, and bladder pain), cystoscopic findings (Hunner's ulcer or bladder bleeding after hydrodistension) and exclusion of confusable diseases. Cytoscopy or hydrodistension is crucial for definite diagnosis. Hypersensitive bladder syndrome (bladder hypersensitivity, usually associated with urinary frequency, with or without bladder pain) can be the diagnosis when interstitial cystitis is suspected but not confirmed by the requirements. Unexplainable urinary frequency is highly suggestive of interstitial cystitis.

There are no established diagnostic criteria for IC.8,9 Two approaches have been undertaken; one is to depend on highly specific criteria such as NIDDK research criteria124 and the other is to adapt symptom-based criteria to increase the sensitivity of diagnosis by advocating the terms such as painful bladder syndrome (PBS) or chronic pelvic pain syndrome (CPPS). In the present guideline, we define IC by three requirements: symptoms such as hypersensitivity, urinary frequency, bladder discomfort and bladder pain, cystoscopic findings proving pathologies in the urinary bladder and exclusion of other diseases explainable for the symptoms and findings.2 Also we define hypersensitive bladder syndrome (HBS) as a symptom complex of bladder hypersensitivity, usually associated with urinary frequency, with or without bladder pain.23 HBS may be used as a tentative diagnosis for the condition that is suspected of IC but has not fulfilled the three requirements for IC diagnosis. Of primary importance in practice is to suspect IC when a patient complains of unexplainable urinary frequency.125–127

Symptoms

Common symptoms of IC include urinary frequency, nocturia, urinary urgency, bladder hypersensitivity, bladder discomfort, and bladder pain.116 These symptoms are collectively called hypersensitive bladder syndrome (HSB) in this guideline. Symptoms are susceptible to dietary, environmental and mental stress with variable remissions and exacerbations.128 The onset of symptoms may be either gradual or rapid.129 O'Leary- Sant's Symptom and Problem Indices are most commonly used for the symptom assessment,130 although the ‘urgency’ is not related to incontinence in many patients.131,132 Other symptom scales including Wisconsin Symptom Instrument133 were equally responsive and could be used as the assessment tool.134 Symptom scores alone have sufficient specificity to serve as the diagnostic indicator,135 and the typical symptoms are highly diagnostic of IC.136 The most typical symptom of IC would be bladder pain, especially pain worsened during holding urine and relieved after voiding. Pain may be felt in the perineum, in the pelvis, or during sexual intercourse.137,138 However, it should be noted that a substantial portion of patients do not complain of pain.22,111,139,140

Clinical examinations

Tenderness in the bladder may be noted by pelvic examination. Pain or tenderness at a specific area of the pelvic floor, in particular unilaterally, may indicate pelvic floor muscle disorder. Urinalysis usually shows no abnormality,141 although microscopic hematuria is noted in a substantial portion of cases.142 Voiding recording is indispensable to confirm decreases in voided volume or functional bladder capacity (e.g. less than 200 mL).11 In urodynamic studies detrusor overactivity may be present. Reduced bladder capacity without detrusor overactivity (bladder hypersensitivity) is suggestive of IC.24,143,144 Pain but not detrusor overactivity elicited by ice-water test is highly predictive of bladder hypersensitivity.145

Cystoscopy

Cystoscopy is needed to identify Hunner's ulcer,146 the positive specific findings of IC. It can also identify other pathologies in the bladder (e.g. bladder stone or cancer).116 In patients with untreated IC, a strong correlation between pain and cystoscopic findings was observed.147 Typically an ulcer is recognized as a well-demarcated reddish mucosal lesion lacking in the normal capillary structure. It is occasionally associated with covering fibrin clots and scars in the vicinity. Even a touch of the lesion by the endoscope may cause bleeding (Fig. 1). The ulcers are more readily recognized by narrow-band imaging cystoscopy.148 Occasionally ‘Hunner's ulcer’ is observed as a slightly reddish mucosal spot or only a convergent scar. We propose a new term, atypical Hunner's ulcer, for such small ambiguous lesions (Fig. 2). Atypical Hunner's ulcer may be overlooked without intentional search for the lesion. It usually undergoes ruptures and massive bleeding after hydrodistension and thus may be definitely diagnosed after hydrodistension. Importantly atypical ulcers should be treated by fulguration similarly for typical Hunner's ulcers. These lesions appear most commonly at the boundaries between the bladder dome and the posterior or lateral walls. It is important to watch the bladder mucosa from the early phase of filling, since Hunner's ulcer and especially atypical Hunner's ulcer may be obscured early after bladder distension. In patients without Hunner's ulcer or atypical Hunner's ulcer the entire mucosa appears to be fairly normal (non-ulcer type), although bladder capacity is reduced in most cases. Cystoscopy is required not only for the diagnosis of IC but for the differential diagnosis of ulcer type IC and non-ulcer type IC, which significantly differ in therapeutic responses.37,149,150

image

Figure 1. Hunner's ulcer. Hunner's ulcer is a well-demarcated reddish mucosal lesion lacking in the normal capillary structure. It is occasionally associated with covering fibrin clots and scars in the vicinity. Even a touch of the lesion by the endoscope may cause bleeding.

Download figure to PowerPoint

image

Figure 2. Atypical Hunner's ulcer. Atypical Hunner's ulcer is observed as a slightly reddish mucosal spot or only a convergent scar, and may be overlooked without careful observations. It usually undergoes ruptures and massive bleeding after hydrodistension, and thus is diagnosed after hydrodistension.

Download figure to PowerPoint

Hydrodistension

Hydrodistension is over-distending the bladder by hydrostatic pressure. It is usually carried out under general or spinal anesthesia (refer to treatment section for technical details). The procedure can be carried out using only mucosal anesthesia to confirm the diagnosis of IC at the office (diagnostic hydrodistension test). The diagnostic hydrodistension cannot distend the bladder fully due to inadequate anesthesia, thus the therapeutic efficacy is limited compared with that under adequate anesthesia. In most cases of IC the maximum bladder capacity is decreased (e.g. less than 500 mL). The ulcers, typical or atypical, sometimes rupture with distension, and massive or waterfall bleeding occurs on deflation from the affected sites. Non-ulcer type IC also shows mucosal bleeding after deflation, which varies in size, from a very limited area to the whole bladder, and in severity, from spotty bleeding from the bladder mucosa (glomerulations) to rainy bleeding. The findings are at present the sole objective and positive diagnosis bases for non-ulcer type IC.116 Despite the remaining doubt as to the sensitivity28 and specificity29,30 of the post-distension bleeding, the severity of bleeding had positive correlations with IC symptoms.151 Because of the importance of the cystoscopic findings, they should be recorded before and after distension in a standardized way (Figs 3,4).

image

Figure 3. Symbols to be used for describing cystoscopic findings.

Download figure to PowerPoint

image

Figure 4. Examples of cystoscopic findings at hydrodistension. Case 1: Hypervascular area was found on the right wall before hydrodistension. After hydrodistension, glomerulations in the posterior wall and rainy bleeding from the right wall were observed. The biopsy specimen was obtained from the left wall. Case 2: An ulcer extending from the right wall to the dome was found. On the corresponding left wall scars accompanied by the hypervascular area was observed. After hydrodistension, the ulcer turned into a rupture and started waterfall bleeding. Rupture and massive bleeding also observed in the scarred lesion (atypical Hunner's ulcer). Biopsy was taken from the retrotrigonal area.

Download figure to PowerPoint

Bladder biopsy

Bladder biopsy is not an essential part of diagnosis, as no specific histological findings for IC have been identified.139,152–154 Mast cell infiltration is often encountered, especially in ulcer-type IC. Its clinical significance would be ruling-out intraepithelial carcinoma and clarifying the histopathology of the patient.155 Biopsy is advised after hydrodistension to avoid risk of bladder rupture,155 although histological findings may be affected by the procedure.

Potassium sensitivity test

This test measures exacerbation of bladder pain after instilling potassium solution intravesically. IC patients tend to experience pain exacerbation to a greater extent, presumably due to increased permeability of the bladder mucosa to the solvent.156 The clinical value, however, would be limited due to high false-positive and false-negative rates and invasiveness of the procedure.157–160 Intravesical potassium may not simply act on urothelial sensory nerve endings; it may also stimulate detrusor muscle contraction.161

Urinary markers

Various kinds of urinary markers have been studied, among which the antiproliferative factor (APF) appears to be promising.162,163 Bladder distention altered urine APF activity and heparin-binding epidermal growth factor-like growth factor (HB-EGF) level toward normal.164 Increased levels of EGF and HB-EGF are implicated with inward potassium current.165 Other urinary markers included nitric oxide, histamine, methylhistamine, and interleukin-6 (IL-6).166,167 Four proteins that differed significantly between IC and controls were identified, with uromodulin and two kininogens higher for controls and inter-alpha-trypsin inhibitor heavy chain H4 higher for IC.168 Urinary concentration of neutrophile elastase increased in patients with pain and small bladder capacity.169 These markers are not necessarily precise predictors of ulcer and/or symptom severity.170

Exclusion of confusable diseases

Diseases to be excluded are listed in Table 1. It should be noted that IC coexists with these diseases.

Table 1.  Confusable diseases with interstitial cystitis
Bladder diseasesOveractive bladder, neurogenic bladder, bladder cancer, bladder calculus, radiation cystitis
Prostate and urethral diseasesProstatic hypertrophy, prostate cancer, urethral diverticulum, urethral stricture
Genitourinary infectionsBacterial cystitis, urethritis, prostatitis
Gynecologic diseasesEndometriosis, uterine myoma, vaginitis, climacteric disturbance
Other conditionsPolyuria, pelvic floor muscle pain

Recommended tests

Diagnostic tests were classified according to recommendation level (mandatory, recommended or optional) in Table 2.

Table 2.  Recommended tests for diagnosis of interstitial cystitis
MandatoryRecommendedOptional
  1. QOL, quality of life.

Clinical historyUrine cultureUltrasonography
Physical examinationsUrine cytologyUrodynamic study
UrinalysisSymptom scoresX-ray examination
QOL scoresPotassium test
Frequency-volume chartBiopsy
Residual urine measurement 
Prostate-specific antigen
Cystoscopy and/or hydrodistension

Treatment

  1. Top of page
  2. Abstract
  3. Introduction
  4. Methods
  5. Definition
  6. Etiology and pathogenesis
  7. Epidemiology
  8. Quality of life
  9. Diagnosis
  10. Treatment
  11. Assessment of therapeutic effectiveness
  12. Clinical algorithm
  13. References

Numerous therapeutic options are available for interstitial cystitis; however, most of them lack in high level evidence, leaving a few modalities as the recommended treatments.

The grade of recommendation for each treatment was determined by examining not only the level of evidence but the variability of efficacy, magnitude of efficacy, clinical applicability, morbidity and cost (Table 3), and is summarized in Table 4. A detailed and thorough consideration on the recent status is available elsewhere.171

Table 3.  The level of evidence and the grade of recommendation
  • Determined by the level of evidence, the variability of efficacy, magnitude of efficacy, clinical applicability, morbidity and cost.

Level of evidence
1Evidence obtained from multiple randomized controlled trials (RCTs)
2Evidence obtained from a single RCT or low quality RCTs
3Evidence obtained from non-randomized controlled studies
4Evidence obtained from observational studies or case series
5Evidence obtained from case studies or expert opinions
Grade of recommendation
AHighly recommended
BRecommended
CNo clear recommendation possible
DNot recommended
Table 4.  Treatments for interstitial cystitis
Treatment Grade of recommendationSuggested doses
  1. †Only for the treatments with grade of recommendation B and C. BCG, bacillus Calmette-Guerin; DMSO, dimethylsulfoxide; TENS, transcutaneous electric nerve stimulation; TUR, transurethral resection.

Conservative treatmentBehavior therapyB   
Stress reductionB   
Diet manipulationB   
Physical therapy C  
Hydrodistension B   
Medical treatmentPentosan polysulfateB  300 mg/day
AmitriptylineB  10–75 mg/day
Hydroxyzine C 25–75 mg/day
Suplatast tosilate C 300–600 mg/day
Cyclosporine A C 3 mg/kgBW/day
Steroid (predonisolone) C 5–25 mg/day
Cimetidine C 600 mg/day
Antibacterial agent  D 
L-arginine  D 
Intravesical instillation or bladder wall injectionDMSOB  50 mL of 50% solution
Heparin C 10 000 units
Hyaluronic acid C 40 mg
Chondroitin sulfate C 0.2–2%
Pentosan polysulfate C 300 mg
Oxybutynin C 0.01%
Lidocaine C 4%
Resiniferatoxin C 10–100 nM
Botulinum toxin C 100–200 IU
BCG  D 
Other treatmentsTENS C  
Neuromodulation C  
Acupuncture C  
Hyperbaric oxygen therapy C  
TURB  For ulcer-type
Cystectomy, Augmentation C Last resort

Conservative treatment

Grade of recommendation: B or C, Level of evidence for efficacy: 2 to 4

Behavioral therapy including timed voiding, controlled fluid intake, pelvic floor muscle training and bladder training improved symptoms in more than a half of the patients.172,173 Considering that mental stress is heightened in IC patients90 and it aggravates the symptoms, stress reduction such as exercise, bathing, shortening working hours or joining educational programs and patient support groups would be efficacious,94,174–176 which was confirmed by a randomized study.177 Support groups should be helpful, especially for lonely and less educated patients, and are available at http://www.ichelp.com/welcome.htm, http://www.tomonoki.org/ in Japan, or http://www.twica.org.tw in Taiwan. Dietary manipulation by avoiding acidic beverages, coffee, tea, soda, spicy food, artificial sweetener and alcohol may be beneficial.178–183 Each patient should be counseled to avoid the food that aggravates his or her symptoms.184–188 Physical therapy such as biofeedback and soft tissue massage relieves urinary frequency, bladder pain or coital pain probably through the relaxation of the pelvic floor muscles.189–195 To maximize the efficacy, however, the supervision by specialists may be required.

Medical treatment

Pentosan polysulfate

Grade of recommendation: B, Level of evidence for efficacy: 2  The glycosaminoglycan (GAG) layer is a non-specific protective mechanism of the bladder mucosa, and its deficiency is implicated with pathogenesis of IC. Pentosan polysulfate (PPS) is believed to repair the damaged GAG layer, but only 3–6% of orally administered PPS is excreted in the urine.196 Two open trials showed modest symptom improvement.197,198 The results of placebo-controlled double blind studies are conflicting,199–201 and there is no detectable dose-response relationship.202 PPS takes 3–6 months until the effect is seeable, and the effect is restricted to only about a quarter of patients. Initiating PPS treatment within 6 months of the diagnosis may be associated with greater improvement.203 Side effects are rare, including hair loss, diarrhea, nausea and headache in a long-term administration.201

Amitriptyline

Grade of recommendation: B, Level of evidence for efficacy: 2  Amitriptyline is expected to inhibit mast cell activity by blocking histamine H1 receptor and to modify pain transmission in the central nervous system by inhibiting serotonin and noradrenalin reuptake. Non-controlled studies demonstrated improvement of frequency and bladder pain in 26–73% of patients.204–207 In a prospective double blind study O'Leary & Sant's symptom score was reduced by more than 30% in 42% of the patients in the amitriptyline group, while it was only 13% in the placebo group.208 The efficacy was demonstrated in a long-term study.209 Adverse events were mild to moderate dry mouth and drowsiness. The response to tricyclic antidepressant therapy was related to the Arg16Gly polymorphism.210

Hydroxyzine

Grade of recommendation: C, Level of evidence for efficacy: 4  An experimental211 and some open-labeled studies have suggested efficacy in about half of patients211–215 with slight to moderate drowsiness as the adverse event. In a randomized comparative study, no significant difference was found between hydroxyzine and placebo, although a tendency towards a favorable effect of hydroxyzine was noted.216

Suplatast tosilate

Grade of recommendation: C, Level of evidence for efficacy: 4   Suplatast tosilate inhibits production of IgE, IL-4 and IL-5, and is efficacious for allergic diseases. A report from Japan suggested increase in bladder volume and symptomatic improvement in the majority of patients without serious side effects.217 No significant adverse event is known. In a mouse model it inhibited the release of histamine and tumor necrosis facto alpha (TNF-α) through a mechanism other than direct mast cell inhibition.218 It improves bladder function and pathological changes in hydrochloride (HCl)-induced cystitis rats.219

Cyclosporine A

Grade of recommendation: C, Level of evidence for efficacy: 2  The efficacy of cyclosporine was reported in open trials.220,221 In a randomized study comparing cyclosporine with pentosan polysulfate sodium, the response rate was 75% for cyclosporine compared with 19% for pentosan polysulfate sodium, and the response was related to a reduction of urinary EGF.222,223 Further studies were warranted, as adverse events are a concern.

Steroid

Grade of recommendation: C, Level of evidence for efficacy: 4   Efficacy of predonisolone for IC symptoms is suggested in a study, but hydrodistension was carried out simultaneously with predonisolone.224 Adverse events associated with long-term administration are a major concern.205 It may be indicated for ulcer type IC unresponsive to other treatments166,225 or IC related with autoimmune diseases.

Cimetidine

Grade of recommendation: C, Level of evidence for efficacy: 2   Cimetidine is a histamine H2-receptor antagonist. Three un-controlled studies indicated about 70% efficacy rate in IC.226–228 A randomized double blind study225 on 36 patients demonstrated a significant improvement in suprapubic pain and frequency compared with a placebo group; however, the detail of the study is unclear.229

Antibacterial agent

Grade of recommendation: D, Level of evidence for non-efficacy: 2   In a randomized placebo-controlled study, antibiotics including rifampin, doxycycline, erythromycin, metronidazole, clindamycin, amoxicillin and ciprofloxacin were shown to have no significant therapeutic effect over placebo.230 Adverse effects were more often in active arms.

L-arginine

Grade of recommendation: D, Level of evidence for non-efficacy: 1   L-arginine, a natural substrate of nitric oxide synthase (NOS), may re-activate NOS activity, which is suppressed in IC, and relieve symptoms.231 Another study, however, indicated no significant change in NO levels in the bladder and no improvement in symptoms.232 No significant effect was confirmed by subsequent double blind studies.233,234

Intravesical instillation or bladder wall injection

Dimethylsulfoxide

Grade of recommendation: B, Level of evidence for efficacy: 2   Dimethylsulfoxide (DMSO) is claimed to have anti-inflammatory, analgesic, muscle relaxant and collagenolytic effects. It prompted nitric oxide release from dorsal ganglion neurons and urinary bladder.235 In randomized236 and non-randomized237–240 studies, an approximately 80% improvement rate has been reported and the efficacy was favored for ulcer-type IC. Most patients recognized a garlic-like odor, and a few patients felt bladder spasm possibly due to mast cell degranulation.240 Periodic ophthalmic examinations are advisable as cataract has been reported in an animal study. Usually a solution of 50% DMSO diluted by physiological saline or distilled water is instilled into the bladder, and retained in the bladder for 10 to 20 min.241 The interval varies from a few times a week to every few months.

Heparin

Grade of recommendation: C, Level of evidence for efficacy: 4   Heparin is expected to function as glycosaminoglycan (GAG) layer on the bladder urothelium. More than a half of patients experienced symptom relief without significant adverse events in open trials.242–244 A randomized comparative study is necessary to obtain conclusive evidence. Instillation with lidocaine may be more efficacious.245

Hyaluronic acid

Grade of recommendation: C, Level of evidence for efficacy: 4   Hyaluronic acid, a glycoprotein, could repair the deficient GAG layer. Many reports suggested a long-lasting moderate efficacy with no significant toxicity.246–252 However, a recent randomized double blind study conducted in 2004 demonstrated no better efficacy than placebo (unpubl. data).

Chondroitin sulfate

Grade of recommendation: C, Level of evidence for efficacy: 4   Chondroitin sulfate, another glycoprotein, is known for its efficacy in open studies.253–255 Combined instillation of hyaluronic acid and chondroitin sulfate in refractory interstitial cystitis resulted in significant symptomatic improvement.256 Confirmatory studies are warranted.

Pentosan polysulfate

Grade of recommendation: C, Level of evidence for efficacy: 2   Pentosan polysulfate (PPS), instilled intravesically, may directly replenish the deficient GAG layer. A double-blind placebo-controlled study indicated its efficacy, although the sample number was so small (n = 20) and the magnitude of efficacy was limited.257 The combined use of intravesical and oral PPS is proposed as a therapeutic option.258

Oxybutynin

Grade of recommendation: C, Level of evidence for efficacy: 2  A single randomized trial indicated symptomatic resolution by intravesical instillation of oxybutynin in addition to bladder training.259

Lidocaine (with electromotive drug administration)

Grade of recommendation: C, Level of evidence for efficacy: 4   Lidocaine is a local anesthetic and relieves pain by blocking sensory nerves in the bladder, although pain relief lasts for a short time.260–263 Alkalization or electromotive drug administration (EMDA) of lidocaine is attempted to promote absorption.

Resiniferatoxin

Grade of recommendation: C, Level of evidence for efficacy: 4, non-efficacy: 2  Capsaicin, a C-fiber afferent neurotoxin, may alleviate the symptoms by desensitizing bladder afferents.264 Resiniferatoxin is more potent than capsaicin in desensitizing C-fibers with less irritation. Clinical efficacy was demonstrated clearly in studies of small sample size,26,265–267 but has not been confirmed in placebo-controlled studies.268,269 No particular toxicity was reported.269

Botulinum toxin

Grade of recommendation: C, Level of evidence for efficacy: 4   Botulinum toxin inhibits release of calcitonin gene-related peptide (CGRP) and substance P from afferent nerves and weakens pain response induced by acetic acid or cyclophosphamide in rats.270,271 Small studies indicated symptom relief in IC patients by botulinum toxin injection, single or repeated, into the bladder wall without significant adverse events.272–275 Further studies are warranted to confirm the promising efficacy.

Bacillus Calmette-Guerin

Grade of recommendation: D, Level of evidence for non-efficacy: 1   Bacillus Calmette-Guerin (BCG) is an immunomodulatory agent for the intravesical instillation therapy of bladder cancer, and was beneficial in an open study.276 An article demonstrated beneficial effects of BCG over placebo for IC symptoms.277 However, other studies including a randomized double blind study demonstrated no clinical benefit.278–281 Adverse events may be serious.

Hydrodistension

Grade of recommendation: B, Level of evidence for efficacy: 4 Hydrodistension has been the most common treatment for IC282,283 since the first report in 1930,284 although there has been no randomized comparative study. Most reports consistently indicated an approximately 50% efficacy rate, but the effect often persisted only for about 6 months.205,285–288 The presumed mechanism is that ischemia and metabolic acidosis induced by hydropressure degenerates afferent nerves, leading to reduced bladder pain and increased bladder capacity.176,286,289 Release of growth factors from the interstitum may also be involved. The procedure would be the most reliable intervention and indispensable for diagnosis of non-ulcer type IC (see Diagnosis section).

No standard method for hydrodistension or no significant difference in efficacy among the methods is known.290 Bladder rupture may occur as morbidity during hydrodistension.284,286,291 Prolonged distension may cause bladder necrosis.292 A suggested procedure is as follows.

  • 1
    General or spinal anesthesia at the Th6 level, preferably up to the Th4 level293
  • 2
    Inflate the bladder by physiologic saline by 80 cmH2O with continuous endoscopic observation for possible bladder ruptures. If the infused volume reaches 800–1000 mL before the intravesical pressure achieves 80 cmH2O, the infusion should be terminated.
  • 3
    After inflation of the bladder, maintain the pressure for a few minutes, drain the water, and observe the bladder mucosa for bleeding during the draining.
  • 4
    Procedures may be repeated, although the therapeutic significance of the repetition is unknown.
  • 5
    A urethral catheter can be placed in the bladder overnight.

Other treatments

Transcutaneous electric nerve stimulation

Grade of recommendation: C, Level of evidence for efficacy: 4   Transcutaneous electric nerve stimulation (TENS) is expected to eliminate pain by electrically stimulating peripheral sensory nerves in the skin.294,295 Some articles reported its efficacy for the treatment of ulcer-type IC.296,297 TENS is applicable at the outpatient clinic.

Electrostimulation including sacral nerve neuromodulation

Grade of recommendation: C, Level of evidence for efficacy: 2   Intermittent posterior tibial nerve stimulation somewhat improved less than half of patients.298 Sacral nerve neuromodulation is stimulation of the sacral root S3 or S4 by a permanent device to modulate afferent neural transmission, which results in pain relief, suppression of detrusor overactivity and stabilization of pelvic floor muscles.299,300 Multiple articles showed significant symptom improvement in open299–304 and blind studies.305 However, it requires a surgery for implantation and replacement of the device.

Acupuncture

Grade of recommendation: C, Level of evidence for efficacy: 3   Acupuncture is a traditional and relatively noninvasive therapy, although its precise mechanism of action is unclear.306 The efficacy of acupuncture for IC would be limited and transient, and repeated treatment will be required to maintain the effect.306,307 A large placebo effect is reported.308 It is an outpatient treatment with minimal morbidity.

Hyperbaric oxygen therapy

Grade of recommendation: C, Level of evidence for efficacy: 5, non-efficacy: 2  Hyperbaric oxygen therapy is demonstrated to be beneficial in an open study,309 but not statistically significant in a randomized, sham controlled, double-blind trial.310

Transurethral resection and transurethral coagulation

Grade of recommendation: B (for ulcer type only), Level of evidence for efficacy: 3  Endoscopic resection or fulguration of the bladder tissue diminishes inflammatory cells and hypersensitive sensory nerve endings, expectedly leading to symptomatic resolution. Transurethral resection (TUR) of the ulcer lesions eliminated symptoms for 1 year or longer in about half of patients,311–313 although it is less effective for non-ulcer IC. It is efficacious for patients who are refractory to hydrodistension without fulguration or have relapsed from the precedent TUR.314 Transurethral coagulation (TUC) using laser is an alternative to TUR and comparably effective.315–318 Bladder perforation, hemorrhage, urethral stricture and vesico-ureteral reflux (VUR) are known as the complications of these procedures.

Cystectomy, augmentation, urinary diversion

Grade of recommendation: C (last resort), Level of evidence for efficacy: 4  Surgical removal of the bladder is the last resort, when other treatments have failed to relieve the disabling symptoms.319,320 Supratrigonal cystectomy combined with augmentation cystoplasty using a bowel segment (ileal, ileocoecal, right colon, or sigmoid colon) is the most common procedure, achieving a significant symptomatic improvement.321–323 Results are apparently more favorable for patients with end-stage ulcer-type IC.324,325 Subtrigonal cystectomy would not be appropriate because of difficulties associated with ureteral or urethral anastomosis.326 Patients undergoing cystoplasty need a long-term follow-up for possible morbidities including hydronephrosis and adenocarcinoma in the intestinal portion.327 Total cystectomy and urinary diversion (continent urinary diversion, orthotopic neobladder or ileal conduit) is another option, although necessity of self catheterization or cosmetic concern should be taken into account.328 Pelvic pain or pouch pain may persist after augmentation and cystectomy.329–331 Sporadic reports indicate that urinary diversion with the bladder unresected improved the symptoms.139,332

Assessment of therapeutic effectiveness

  1. Top of page
  2. Abstract
  3. Introduction
  4. Methods
  5. Definition
  6. Etiology and pathogenesis
  7. Epidemiology
  8. Quality of life
  9. Diagnosis
  10. Treatment
  11. Assessment of therapeutic effectiveness
  12. Clinical algorithm
  13. References

The inclusion and efficacy criteria for clinical trials should be standardized to enhance the clinical research for interstitial cystitis.

New treatments for IC and hypersensitive bladder syndrome will be challenged for efficacy in the future. These diseases or conditions would need special consideration for the study design.333 To enhance the research process, the criteria for inclusion and efficacy assessment should be standardized.

Inclusion criteria

The criteria for enrolment (Table 5) are slight modification of the NIDDK inclusion criteria in 1987.10 Details of inclusion criteria, especially for target symptoms and their severity, should be determined to optimize the sensitivity to detect efficacy of the target treatment. Recent hydrodistension and bladder instillation are included in exclusion criteria in consideration of possible carry-over effects.

Table 5.  Inclusion/exclusion criteria for clinical research
  • Refer to Cystoscopy in the Diagnosis section of the text.

  • ‡Not included in the National Institute of Diabetes and Digestive Kidney Diseases (NIDDK) criteria.

  • §

    NIDDK exclusion criteria deleted; age under 18, absence of urgency, capacity greater than 350 mL, involuntary bladder contractions by urodynamics, daytime frequency less than five times, nocturia less than two times, and symptoms relieved by antibiotics or anticholinergics.

  • Duration less than 9 months in NIDDK criteria.

Inclusion criteriaHunner's ulcer, atypical Hunner's ulcer or glomerulations on cystoscopy, AND lower urinary tract symptoms (urinary frequency, bladder hypersensitivity, urinary urgency, bladder pain)
Exclusion criteria§Duration less than 3 months, lower urinary tract infection in 3 months, hydrodistension in 3 months, bladder instillation in 1 month, neurogenic bladder, lower urinary tract calculi, genital herpes, bladder cancer, prostate cancer, urethral cancer, gynecologic cancer, urethral diverticulum, vaginitis, tuberculous cystitis, radiation cystitis and drug-induced cystitis

Efficacy criteria

Efficacy assessment method

There is no gold standard for efficacy assessment.333 The optimal method should be defined before starting study. The examples are given below.

  • • 
    Aggregated or composite symptom scores
  • • 
    Individual symptom scores
  • • 
    Variables of voiding recording (i.e. voiding frequency and single voided volume)
  • • 
    QOL scores
  • • 
    Global response assessment by patients' subjective impressions (i.e. Table 6134)
Table 6.  An example of a questionnaire for overall improvement by patients' subjective impressions
Have your bladder symptoms been improved or worsened by the treatment?
Choose one statement which best fits to your impression.
1. Markedly improved
2. Moderately improved
3. Slightly improved
4. No change
5. Slightly worsened
6. Moderately worsened
7. Markedly worsened
Potential factors that may affect the efficacy assessment
  • • 
    Symptom severity
  • • 
    Presence or absence of bladder pain, and its intensity
  • • 
    Bladder capacity
  • • 
    Presence or absence of an ulcer (ulcer type, non-ulcer type)149
  • • 
    Gender
  • • 
    Age
Other considerations
  • • 
    A placebo-controlled (or standard-treatment-controlled) double-blind study is highly recommended for pharmaceutical therapy because of a high placebo effect.
  • • 
    Efficacy assessment should be carried out at 3 months after intervention. Assessment of long-term efficacy (e.g. at 6 months or 12 months) is also recommended.

Clinical algorithm

  1. Top of page
  2. Abstract
  3. Introduction
  4. Methods
  5. Definition
  6. Etiology and pathogenesis
  7. Epidemiology
  8. Quality of life
  9. Diagnosis
  10. Treatment
  11. Assessment of therapeutic effectiveness
  12. Clinical algorithm
  13. References

The algorithm is constructed to guide the care providers to the proper management in the diagnosis and treatment of patients with hypersensitive bladder syndrome (Fig. 5).

image

Figure 5. Clinical algorithm for hypersensitive bladder syndrome. This algorithm is for subjects presenting with hypersensitive bladder symptom syndrome, which is defined as bladder hypersensitivity, usually associated with urinary frequency, with or without bladder pain. The basic evaluation consists of the mandatory evaluation (history taking, physical findings, and urinalysis), recommended evaluation (urine culture, urine cytology, symptom scores, quality of life [QOL] scores, frequency-volume chart, residual urine measurement, and prostate-specific antigen), or optional evaluation (urodynamic tests, imaging tests, and potassium test). After basic evaluation, one may follow three choices. (A) When interstitial cystitis is highly likely, hydrodistension under adequate anesthesia should be considered. Less invasive treatments may be administered without definite diagnosis, or attempted concomitantly with hydrodistension. (B) When interstitial cystitis is likely or no other diseases are identified, three choices are available. First, empirical therapy with less invasive treatments for interstitial cystitis (conservative, medical or instillation treatments) are attempted without a definite diagnosis, and the second or third choice is to be considered when the empirical therapy fails (a). Second, one can directly proceed to hydrodistension under adequate anesthesia (b: see below). Third, cystoscopy is considered to identify Hunner's ulcer or other pathologies in the bladder. If no abnormality is found, a diagnostic hydrodistension test can be carried out. The test is an office-base diagnostic procedure to confirm the glomerulations (spotty bleeding from the bladder mucosa) by incomplete bladder distension under mucosal anesthesia (c). (C) When interstitial cystitis is unlikely or other diseases are identified, appropriate treatments should be initiated. Other diseases that may cause hypersensitive bladder syndrome include urinary calculi, bladder cancer, prostate cancer, urethral cancer, bacterial cystitis, prostatitis, urethritis, neurogenic bladder, overactive bladder, benign prostatic hyperplasia, urethral stricture, urethral diverticulum, polyuria, and so on. Should the treatment provide no sufficient improvement, consider re-evaluation for the accurate diagnosis. Hydrodistension under general or spinal anesthesia not only confirms the diagnosis of interstitial cystitis but provides therapeutic benefit to the patients. Hunner's ulcers or atypical Hunner's ulcers, if present, should be endoscopically coagulated or resected. When sufficient improvement cannot be achieved or the symptoms recurred after initial treatments, combined or repeated treatments should be considered. Cystectomy is the last resort.

Download figure to PowerPoint

References

  1. Top of page
  2. Abstract
  3. Introduction
  4. Methods
  5. Definition
  6. Etiology and pathogenesis
  7. Epidemiology
  8. Quality of life
  9. Diagnosis
  10. Treatment
  11. Assessment of therapeutic effectiveness
  12. Clinical algorithm
  13. References
  • 1
    Homma Y, Ueda T, Ito T, Takei M, Tomoe H. Clinical Guidelines for Interstitial Cystitis. Blackwell Publishing, Tokyo, 2007.
  • 2
    Homma Y, Ueda T, Ito T, Takei M, Tomoe H. Japanese guideline for diagnosis and treatment of interstitial cystitis. Int. J. Urol. 2009; 16: 416.
  • 3
    International Consultation on Interstitial Cystitis Japan (ICICJ). Int. J. Urol. 2003; 10: (Suppl).
  • 4
    Comfortable Urology Network. 2nd ICICJ. Comfortable Urology Network, Kyoto, 2008.
  • 5
    Hanno P, Baranowski A, Fall M et al. Painful bladder syndrome (including interstitial cystitis). In: AbramsP, CardozoL. KhouryS, WeinA (eds). Incontinence. Health Publication, St Helier, 2005; 1455520.
  • 6
    Fall M, Baranowski AP, Elneil S et al. Guidelines on chronic pelvic pain. In European Association of Urology Guidelines, 2008 edn. Available from URL: http://www.uroweb.org/files/uploaded_2326_files/guidelines/chronicpelvicpain.pdf
  • 7
    Parsons JK, Parsons CL. The historical origins of interstitial cystitis. J. Urol. 2004; 171: 202.
  • 8
    Hanno P, Nordling J, Van Ophoven A. What is new in bladder pain syndrome/interstitial cystitis? Curr. Opin. Urol. 2008; 18: 3538.
  • 9
    Goldman HB. Interstitial cystitis – the great enigma. J. Urol. 2000; 164: 1921.
  • 10
    Hanno PM, Landis JR, Matthews-Cook Y, Kusek J, Nyberg L Jr. The diagnosis of interstitial cystitis revisited: lessons learned from the National Institutes of Health Interstitial Cystitis Database study. J. Urol. 1999; 161: 5537.
  • 11
    Sant GR, Hanno PM. Interstitial cystitis: current issues and controversies in diagnosis. Urology 2001; 57: 828.
  • 12
    Diokno AC, Homma Y, Sekiguchi Y, Suzuki Y. Interstitial cystitis, gynecologic pelvic pain, prostatitis, and their epidemiology. Int. J. Urol. 2003; 10 (Suppl): S36.
  • 13
    Leiby BE, Landis JR, Propert KJ, Tomaszewski JE. Discovery of morphological subgroups that correlate with severity of symptoms in interstitial cystitis: a proposed biopsy classification system. J. Urol. 2007; 177: 1428.
  • 14
    Bogart LM, Berry SH, Clemens JQ. Symptoms of interstitial cystitis, painful bladder syndrome and similar diseases in women: a systematic review. J. Urol. 2007; 177: 4506.
  • 15
    Abrams P, Cardozo L, Fall M et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol. Urodyn. 2002; 21: 16778.
  • 16
    Abrams P, Baranowski A, Berger RE, Fall M, Hanno P, Wesselmann U. A new classification is needed for pelvic pain syndromes – are existing terminologies of spurious diagnostic authority bad for patients? J. Urol. 2006; 175: 198990.
  • 17
    Dalpiaz O, Kerschbaumer A, Mitterberger M, Pinggera G, Bartsch G, Strasser H. Chronic pelvic pain in women: still a challenge. BJU Int. 2008; 102: 10615.
  • 18
    Van De Merwe JP, Nordling J, Bouchelouche P et al. Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: an ESSIC proposal. Eur. Urol. 2008; 53: 607.
  • 19
    Clauw DJ, Schmidt M, Radulovic D, Singer A, Katz P, Bresette J. The relationship between fibromyalgia and interstitial cystitis. J. Psychiatr. Res. 1997; 31: 12531.
  • 20
    Warren JW, Meyer WA, Greenberg P, Horne L, Diggs C, Tracy JK. Using the International Continence Society's definition of painful bladder syndrome. Urology 2006; 67: 113842, discussion 1142–3.
  • 21
    International Association for the Study of Pain. Part III: Pain Terms: A Current List with Definitions and Notes on Usage. In: MerskeyH and BogdukN (eds). Classification of Chronic Pain, 2nd edn, IASP Task Force on Taxonomy, IASP Press, Seattle, 1994; 209214.
  • 22
    Irwin P, Samsudin A. Reinvestigation of patients with a diagnosis of interstitial cystitis: common things are sometimes common. J. Urol. 2005; 174: 5847, discussion 587.
  • 23
    Homma Y. Lower urinary tract symptomatology: its definition and confusion. Int. J. Urol. 2008; 15: 3543.
  • 24
    Frazer MI, Haylen BT, Sissons M. Do women with idiopathic sensory urgency have early interstitial cystitis? Br. J. Urol. 1990; 66: 2748.
  • 25
    Liu L, Mansfield KJ, Kristiana I, Vaux KJ, Millard RJ, Burcher E. The molecular basis of urgency: regional difference of vanilloid receptor expression in the human urinary bladder. Neurourol. Urodyn. 2007; 26: 4338; discussion 439; discussion 451–3.
  • 26
    Apostolidis A, Gonzales GE, Fowler CJ. Effect of intravesical Resiniferatoxin (RTX) on lower urinary tract symptoms, urodynamic parameters, and quality of life of patients with urodynamic increased bladder sensation. Eur. Urol. 2006; 50: 1299305.
  • 27
    Yamaguchi O, Honda K, Nomiya M et al. Defining overactive bladder as hypersensitivity. Neurourol. Urodyn. 2007; 26: 9047.
  • 28
    Shear S, Mayer R. Development of glomerulations in younger women with interstitial cystitis. Urology 2006; 68: 2536.
  • 29
    Furuya R, Masumori N, Furuya S, Oda T, Takahashi S, Takeuchi M. Glomerulation observed during transurethral resection of the prostate for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia is a common finding but no predictor of clinical outcome. Urology 2007; 70: 9226.
  • 30
    Waxman JA, Sulak PJ, Kuehl TJ. Cystoscopic findings consistent with interstitial cystitis in normal women undergoing tubal ligation. J. Urol. 1998; 160: 16637.
  • 31
    Parsons CL, Lilly JD, Stein P. Epithelial dysfunction in nonbacterial cystitis (interstitial cystitis). J. Urol. 1991; 145: 7325.
  • 32
    Keay S, Kleinberg M, Zhang CO, Hise MK, Warren JW. Bladder epithelial cells from patients with interstitial cystitis produce an inhibitor of heparin-binding epidermal growth factor-like growth factor production. J. Urol. 2000; 164: 211218.
  • 33
    Keay S, Seillier-Moiseiwitsch F, Zhang CO, Chai TC, Zhang J. Changes in human bladder epithelial cell gene expression associated with interstitial cystitis or antiproliferative factor treatment. Physiol. Genomics 2003; 14: 10715.
  • 34
    Zhang CO, Wang JY, Koch KR, Keay S. Regulation of tight junction proteins and bladder epithelial paracellular permeability by an antiproliferative factor from patients with interstitial cystitis. J. Urol. 2005; 174: 23827.
  • 35
    Laguna P, Smedts F, Nordling J et al. Keratin expression profiling of transitional epithelium in the painful bladder syndrome/interstitial cystitis. Am. J. Clin. Pathol. 2006; 125: 10510.
  • 36
    Southgate J, Varley CL, Garthwaite MA et al. Differentiation potential of urothelium from patients with benign bladder dysfunction. BJU Int. 2007; 99: 150616.
  • 37
    Zeng Y, Wu XX, Homma Y et al. Uroplakin III-delta4 messenger RNA as a promising marker to identify nonulcerative interstitial cystitis. J. Urol. 2007; 178: 13227; discussion 1327.
  • 38
    Hauser PJ, Dozmorov MG, Bane BL, Slobodov G, Culkin DJ, Hurst RE. Abnormal expression of differentiation related proteins and proteoglycan core proteins in the urothelium of patients with interstitial cystitis. J. Urol. 2008; 179: 7649.
  • 39
    Kumar V, Chapple CR, Surprenant AM, Chess-Williams R. Enhanced adenosine triphosphate release from the urothelium of patients with painful bladder syndrome: a possible pathophysiological explanation. J. Urol. 2007; 178: 15336.
  • 40
    Rastogi P, Rickard A, Dorokhov N, Klumpp DJ, McHowat J. Loss of prostaglandin E2 release from immortalized urothelial cells obtained from interstitial cystitis patient bladders. Am. J. Physiol. Renal Physiol. 2008; 294: F112935.
  • 41
    Erickson DR, Schwarze SR, Dixon JK, Clark CJ, Hersh MA. Differentiation associated changes in gene expression profiles of interstitial cystitis and control urothelial cells. J. Urol. 2008; 180: 26817.
  • 42
    Peeker R, Enerback L, Fall M, Aldenborg F. Recruitment, distribution and phenotypes of mast cells in interstitial cystitis. J. Urol. 2000; 163: 100915.
  • 43
    Hofmeister MA, He F, Ratliff TL, Mahoney T, Becich MJ. Mast cells and nerve fibers in interstitial cystitis (IC): an algorithm for histologic diagnosis via quantitative image analysis and morphometry (QIAM). Urology 1997; 49: 417.
  • 44
    Fall M, Johansson SL, Aldenborg F. Chronic interstitial cystitis: a heterogeneous syndrome. J. Urol. 1987; 137: 358.
  • 45
    Dundore PA, Schwartz AM, Semerjian H. Mast cell counts are not useful in the diagnosis of nonulcerative interstitial cystitis. J. Urol. 1996; 155: 8857.
  • 46
    Ueda T, Tamaki M, Ogawa O, Yoshimura N. Over expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in patients with interstitial cystitis and bladder carcinoma. J. Urol. 2002; 167: 34751.
  • 47
    Koskela LR, Thiel T, Ehren I, De Verdier PJ, Wiklund NP. Localization and expression of inducible nitric oxide synthase in biopsies from patients with interstitial cystitis. J. Urol. 2008; 180: 73741.
  • 48
    Bouchelouche K, Bouchelouche P. Cysteinyl leukotriene D4 increases human detrusor muscle responsiveness to histamine. J. Urol. 2006; 176: 3616.
  • 49
    Sakthivel SK, Singh UP, Singh S, Taub DD, Novakovic KR, Lillard JW Jr. CXCL10 blockade protects mice from cyclophosphamide-induced cystitis. J. Immune Based Ther. Vaccines 2008; 6: 6.
  • 50
    Domingue GJ, Ghoniem GM, Bost KL, Fermin C, Human LG. Dormant microbes in interstitial cystitis. J. Urol. 1995; 153: 13216.
  • 51
    Lynes W, Sellers R, Shortliffe L. The evidence for occult bacterial infections as a cause for interstitial cystitis. J. Urol. 1989; 141: 268A.
  • 52
    Duncan JL, Schaeffer AJ. Do infectious agents cause interstitial cystitis? Urology 1997; 49: 4851.
  • 53
    Al-Hadithi HN, Williams H, Hart CA et al. Absence of bacterial and viral DNA in bladder biopsies from patients with interstitial cystitis/chronic pelvic pain syndrome. J. Urol. 2005; 174: 1514.
  • 54
    Stanford E, McMurphy C. There is a low incidence of recurrent bacteriuria in painful bladder syndrome/interstitial cystitis patients followed longitudinally. Int. Urogynecol. J. Pelvic Floor Dysfunct. 2007; 18: 5514.
  • 55
    Warren JW, Brown V, Jacobs S, Horne L, Langenberg P, Greenberg P. Urinary tract infection and inflammation at onset of interstitial cystitis/painful bladder syndrome. Urology 2008; 71: 108590.
  • 56
    Soler R, Bruschini H, Freire MP, Alves MT, Srougi M, Ortiz V. Urine is necessary to provoke bladder inflammation in protamine sulfate induced urothelial injury. J. Urol. 2008; 180: 152731.
  • 57
    Parsons CL, Bautista SL, Stein PC, Zupkas P. Cyto-injury factors in urine: a possible mechanism for the development of interstitial cystitis. J. Urol. 2000; 164: 13814.
  • 58
    Chu PS, Ma WK, Wong SC et al. The destruction of the lower urinary tract by ketamine abuse: a new syndrome? BJU Int. 2008; 102: 161622.
  • 59
    Nguan C, Franciosi LG, Butterfield NN, Macleod BA, Jens M, Fenster HN. A prospective, double-blind, randomized cross-over study evaluating changes in urinary pH for relieving the symptoms of interstitial cystitis. BJU Int. 2005; 95: 914.
  • 60
    Rosamilia A, Cann L, Scurry J, Rogers P, Dwyer P. Bladder microvasculature and the effects of hydrodistention in interstitial cystitis. Urology 2001; 57: 132.
  • 61
    Pontari MA, Hanno PM, Ruggieri MR. Comparison of bladder blood flow in patients with and without interstitial cystitis. J. Urol. 1999; 162: 3304.
  • 62
    Yamada T, Nishimura M, Mita H. Increased number of apoptotic endothelial cells in bladder of interstitial cystitis patients. World J. Urol. 2007; 25: 40713.
  • 63
    Peters KM, Carrico DJ, Diokno AC. Characterization of a clinical cohort of 87 women with interstitial cystitis/painful bladder syndrome. Urology 2008; 71: 63440.
  • 64
    Hall SA, Link CL, Pulliam SJ et al. The relationship of common medical conditions and medication use with symptoms of painful bladder syndrome: results from the Boston area community health survey. J. Urol. 2008; 180: 5938.
  • 65
    Weinstock LB, Klutke CG, Lin HC. Small intestinal bacterial overgrowth in patients with interstitial cystitis and gastrointestinal symptoms. Dig. Dis. Sci. 2008; 53: 124651.
  • 66
    Oravisto KJ. Interstitial cystitis as an autoimmune disease. A review. Eur. Urol. 1980; 6: 1013.
  • 67
    Anderson JB, Parivar F, Lee G et al. The enigma of interstitial cystitis – an autoimmune disease? Br. J. Urol. 1989; 63: 5863.
  • 68
    Tan EM. Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv. Immunol. 1989; 44: 93151.
  • 69
    Ochs RL. Autoantibodies and interstitial cystitis. Clin. Lab. Med. 1997; 17: 5719.
  • 70
    Leppilahti M, Tammela TL, Huhtala H, Kiilholma P, Leppilahti K, Auvinen A. Interstitial cystitis-like urinary symptoms among patients with Sjogren's syndrome: a population-based study in Finland. Am. J. Med. 2003; 115: 625.
  • 71
    Lin YH, Liu G, Kavran M et al. Lower urinary tract phenotype of experimental autoimmune cystitis in mouse: a potential animal model for interstitial cystitis. BJU Int. 2008; 102: 172430.
  • 72
    Lee J, Doggweiler-Wiygul R, Kim S, Hill BD, Yoo TJ. Is interstitial cystitis an allergic disorder? A case of interstitial cystitis treated successfully with anti-IgE. Int. J. Urol. 2006; 13: 6314.
  • 73
    Imamov O, Yakimchuk K, Morani A et al. Estrogen receptor beta-deficient female mice develop a bladder phenotype resembling human interstitial cystitis. Proc. Natl Acad. Sci USA 2007; 104: 98069.
  • 74
    Christmas TJ, Rode J, Chapple CR, Milroy EJ, Turner-Warwick RT. Nerve fibre proliferation in interstitial cystitis. Virchows Arch. A Pathol. Anat. Histopathol. 1990; 416: 44751.
  • 75
    Hohenfellner M, Nunes L, Schmidt RA, Lampel A, Thuroff JW, Tanagho EA. Interstitial cystitis: increased sympathetic innervation and related neuropeptide synthesis. J. Urol. 1992; 147: 58791.
  • 76
    Palea S, Artibani W, Ostardo E, Trist DG, Pietra C. Evidence for purinergic neurotransmission in human urinary bladder affected by interstitial cystitis. J. Urol. 1993; 150: 200712.
  • 77
    Zermann DH, Ishigooka M, Doggweiler-Wiygul R, Schubert J, Schmidt RA. Central autonomic innervation of the kidney. What can we learn from a transneuronal tracing study in an animal model? J. Urol. 2005; 173: 10338.
  • 78
    Stefansson K, Wollmann RL, Moore BW. Distribution of S-100 protein outside the central nervous system. Brain Res. 1982; 234: 30917.
  • 79
    Sugimura K, Haimoto H, Nagura H, Kato K, Takahashi A. Immunohistochemical differential distribution of S-100 alpha and S-100 beta in the peripheral nervous system of the rat. Muscle Nerve 1989; 12: 92935.
  • 80
    Peeker R, Aldenborg F, Haglid K, Johansson SL, Rosengren L, Fall M. Decreased levels of S-100 protein in non-ulcer interstitial cystitis. Scand. J. Urol. Nephrol. 1998; 32: 3958.
  • 81
    Peeker R, Aldenborg F, Dahlstrom A, Johansson SL, Li JY, Fall M. Increased tyrosine hydroxylase immunoreactivity in bladder tissue from patients with classic and nonulcer interstitial cystitis. J. Urol. 2000; 163: 111215.
  • 82
    Elbadawi AE, Light JK. Distinctive ultrastructural pathology of nonulcerative interstitial cystitis: new observations and their potential significance in pathogenesis. Urol. Int. 1996; 56: 13762.
  • 83
    Chen MC, Blunt LW, Pins MR, Klumpp DJ. Tumor necrosis factor promotes differential trafficking of bladder mast cells in neurogenic cystitis. J. Urol. 2006; 175: 7549.
  • 84
    Buffington CA. Comorbidity of interstitial cystitis with other unexplained clinical conditions. J. Urol. 2004; 172: 12428.
  • 85
    Lutgendorf SK, Latini JM, Rothrock N, Zimmerman MB, Kreder KJ Jr. Autonomic response to stress in interstitial cystitis. J. Urol. 2004; 172: 22731.
  • 86
    Fenton BW, Durner C, Fanning J. Frequency and distribution of multiple diagnoses in chronic pelvic pain related to previous abuse or drug-seeking behavior. Gynecol. Obstet. Invest. 2008; 65: 24751.
  • 87
    Novi JM, Jeronis S, Srinivas S, Srinivasan R, Morgan MA, Arya LA. Risk of irritable bowel syndrome and depression in women with interstitial cystitis: a case-control study. J. Urol. 2005; 174: 93740.
  • 88
    Peters KM, Kalinowski SE, Carrico DJ, Ibrahim IA, Diokno AC. Fact or fiction – is abuse prevalent in patients with interstitial cystitis? Results from a community survey and clinic population. J. Urol. 2007; 178: 8915; discussion 895.
  • 89
    Link CL, Pulliam SJ, Hanno PM et al. Prevalence and psychosocial correlates of symptoms suggestive of painful bladder syndrome: results from the Boston area community health survey. J. Urol. 2008; 180: 599606.
  • 90
    Fan YH, Lin AT, Wu HM, Hong CJ, Chen KK. Psychological profile of Taiwanese interstitial cystitis patients. Int. J. Urol. 2008; 15: 41618.
  • 91
    Clemens JQ, Brown SO, Calhoun EA. Mental health diagnoses in patients with interstitial cystitis/painful bladder syndrome and chronic prostatitis/chronic pelvic pain syndrome: a case/control study. J. Urol. 2008; 180: 137882.
  • 92
    Goldstein HB, Safaeian P, Garrod K, Finamore PS, Kellogg-Spadt S, Whitmore KE. Depression, abuse and its relationship to interstitial cystitis. Int. Urogynecol. J. Pelvic Floor Dysfunct. 2008; 19: 16836.
  • 93
    Seth A, Teichman JM. Differences in the clinical presentation of interstitial cystitis/painful bladder syndrome in patients with or without sexual abuse histology. J. Urol. 2008; 180: 202933.
  • 94
    Rothrock NE, Lutgendorf SK, Kreder KJ, Ratliff T, Zimmerman B. Stress and symptoms in patients with interstitial cystitis: a life stress model. Urology 2001; 57: 4227.
  • 95
    Theoharides TC, Sant GR. Immunomodulators for treatment of interstitial cystitis. Urology 2005; 65: 6338.
  • 96
    Theoharides TC, Pang X, Letourneau R, Sant GR. Interstitial cystitis: a neuroimmunoendocrine disorder. Ann. N. Y. Acad. Sci. 1998; 840: 61934.
  • 97
    Okragly AJ, Niles AL, Saban R et al. Elevated tryptase, nerve growth factor, neurotrophin-3 and glial cell line-derived neurotrophic factor levels in the urine of interstitial cystitis and bladder cancer patients. J. Urol. 1999; 161: 43841; discussion 441–2.
  • 98
    Abdel-Mageed AB, Ghoniem GM. Potential role of rel/nuclear factor-kappaB in the pathogenesis of interstitial cystitis. J. Urol. 1998; 160: 20003.
  • 99
    Dang K, Lamb K, Cohen M, Bielefeldt K, Gebhart GF. Cyclophosphamide-induced bladder inflammation sensitizes and enhances P2X receptor function in rat bladder sensory neurons. J. Neurophysiol. 2008; 99: 4959.
  • 100
    Nazif O, Teichman JM, Gebhart GF. Neural upregulation in interstitial cystitis. Urology 2007; 69: 2433.
  • 101
    Rudick CN, Chen MC, Mongiu AK, Klumpp DJ. Organ cross talk modulates pelvic pain. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2007; 293: R11918.
  • 102
    Oravisto KJ. Epidemiology of interstitial cystitis. Ann. Chir. Gynaecol. Fenn. 1975; 64: 757.
  • 103
    Leppilahti M, Tammela TL, Huhtala H, Auvinen A. Prevalence of symptoms related to interstitial cystitis in women: a population based study in Finland. J. Urol. 2002; 168: 13943.
  • 104
    Leppilahti M, Sairanen J, Tammela TL, Aaltomaa S, Lehtoranta K, Auvinen A. Prevalence of clinically confirmed interstitial cystitis in women: a population based study in Finland. J. Urol. 2005; 174: 5813.
  • 105
    Temml C, Wehrberger C, Riedl C, Ponholzer A, Marszalek M, Madersbacher S. Prevalence and correlates for interstitial cystitis symptoms in women participating in a health screening project. Eur. Urol. 2007; 51: 8038; discussion 809.
  • 106
    Jones C, Harris M, Nyberg L. Prevalence of interstitial cystitis in the United States. J. Urol. 1994; 151: 423A.
  • 107
    Curhan GC, Speizer FE, Hunter DJ, Curhan SG, Stampfer MJ. Epidemiology of interstitial cystitis: a population based study. J. Urol. 1999; 161: 54952.
  • 108
    Clemens JQ, Meenan RT, Rosetti MC, Gao SY, Calhoun EA. Prevalence and incidence of interstitial cystitis in a managed care population. J. Urol. 2005; 173: 98102; discussion 102.
  • 109
    Clemens JQ, Link CL, Eggers PW, Kusek JW, Nyberg LM Jr, McKinlay JB. Prevalence of painful bladder symptoms and effect on quality of life in black, Hispanic and white men and women. J. Urol. 2007; 177: 13904.
  • 110
    Ito T, Miki M, Yamada T. Interstitial cystitis in Japan. BJU Int. 2000; 86: 6347.
  • 111
    Ito T, Ueda T, Honma Y, Takei M. Recent trends in patient characteristics and therapeutic choices for interstitial cystitis: analysis of 282 Japanese patients. Int. J. Urol. 2007; 14: 106870.
  • 112
    Homma Y, Yamaguchi O, Hayashi K. Epidemiologic survey of lower urinary tract symptoms in Japan. Urology 2006; 68: 5604.
  • 113
    Kennedy CM, Bradley CS, Galask RP, Nygaard IE. Risk factors for painful bladder syndrome in women seeking gynecologic care. Int. Urogynecol. J. Pelvic Floor Dysfunct. 2006; 17:738.
  • 114
    Payne CK, Joyce GF, Wise M, Clemens JQ. Interstitial cystitis and painful bladder syndrome. J. Urol. 2007; 177: 20429.
  • 115
    Clemens JQ, Meenan RT, Rosetti MC, Kimes T, Calhoun EA. Costs of interstitial cystitis in a managed care population. Urology 2008; 71: 77680; discussion 780–1.
  • 116
    Simon LJ, Landis JR, Erickson DR, Nyberg LM. The Interstitial Cystitis Data Base Study: concepts and preliminary baseline descriptive statistics. Urology 1997; 49: 6475.
  • 117
    Michael YL, Kawachi I, Stampfer MJ, Colditz GA, Curhan GC. Quality of life among women with interstitial cystitis. J. Urol. 2000; 164: 4237.
  • 118
    Rothrock NE, Lutgendorf SK, Kreder KJ. Coping strategies in patients with interstitial cystitis: relationships with quality of life and depression. J. Urol. 2003; 169: 2336.
  • 119
    Homma Y. The symptoms of IC and QOL. Voiding Disorders Dig. 2004; 12: 1522 [In Japanese.
  • 120
    Ottem DP, Carr LK, Perks AE, Lee P, Teichman JM. Interstitial cystitis and female sexual dysfunction. Urology 2007; 69: 60810.
  • 121
    Nickel JC, Tripp D, Teal V et al. Sexual function is a determinant of poor quality of life for women with treatment refractory interstitial cystitis. J. Urol. 2007; 177: 18326.
  • 122
    Nickel JC, Parsons CL, Forrest J et al. Improvement in sexual functioning in patients with interstitial cystitis/painful bladder syndrome. J. Sex. Med. 2008; 5: 3949.
  • 123
    Gardella B, Porru D, Ferdeghini F et al. Insight into urogynecologic features of women with interstitial cystitis/painful bladder syndrome. Eur. Urol. 2008; 54: 114551.
  • 124
    Gillenwater JY, Wein AJ. Summary of the National Institute of Arthritis, Diabetes, Digestive and Kidney Diseases Workshop on Interstitial Cystitis, National Institutes of Health, Bethesda, Maryland, August 28–29, 1987. J. Urol. 1988; 140: 2036.
  • 125
    Kusek JW, Nyberg LM. The epidemiology of interstitial cystitis: is it time to expand our definition? Urology 2001; 57: 959.
  • 126
    Dell JR. Chronic pelvic pain of bladder origin: a focus on interstitial cystitis. Int. J. Fertil. Womens Med. 2003; 48: 15462.
  • 127
    Ajibona OO, Kehinde EO. Interstitial cystitis: a review of current concepts of aetiology, diagnosis and therapy. Scand. J. Urol. Nephrol. 2003; 37: 2538.
  • 128
    Lutgendorf SK, Kreder KJ, Rothrock NE, Ratliff TL, Zimmerman B. Stress and symptomatology in patients with interstitial cystitis: a laboratory stress model. J. Urol. 2000; 164: 12659.
  • 129
    Greenberg P, Tracy JK, Meyer WA, Yates T, Diggs C, Warren JW. Short interval between symptom onset and medical care as an indication of rapid onset of interstitial cystitis/painful bladder syndrome. BJU Int. 2007; 100: 599602; discussion 602.
  • 130
    O'Leary MP, Sant GR, Fowler FJ Jr, Whitmore KE, Spolarich-Kroll J. The interstitial cystitis symptom index and problem index. Urology 1997; 49: 5863.
  • 131
    Greenberg P, Brown J, Yates T, Brown V, Langenberg P, Warren JW. Voiding urges perceived by patients with interstitial cystitis/painful bladder syndrome. Neurourol. Urodyn. 2008; 27: 28790.
  • 132
    Diggs C, Meyer WA, Langenberg P, Greenberg P, Horne L, Warren JW. Assessing urgency in interstitial cystitis/painful bladder syndrome. Urology 2007; 69: 21014.
  • 133
    Sirinian E, Azevedo K, Payne CK. Correlation between 2 interstitial cystitis symptom instruments. J. Urol. 2005; 173: 83540.
  • 134
    Propert KJ, Mayer RD, Wang Y et al. Responsiveness of symptom scales for interstitial cystitis. Urology 2006; 67: 559.
  • 135
    Kushner L, Moldwin RM. Efficiency of questionnaires used to screen for interstitial cystitis. J. Urol. 2006; 176: 58792.
  • 136
    Warren JW, Brown J, Tracy JK, Langenberg P, Wesselmann U, Greenberg P. Evidence-based criteria for pain of interstitial cystitis/painful bladder syndrome in women. Urology 2008; 71: 4448.
  • 137
    FitzGerald MP, Brensinger C, Brubaker L, Propert K. What is the pain of interstitial cystitis like? Int. Urogynecol. J. Pelvic Floor Dysfunct. 2006; 17: 6972.
  • 138
    Warren JW, Langenberg P, Greenberg P, Diggs C, Jacobs S, Wesselmann U. Sites of pain from interstitial cystitis/painful bladder syndrome. J. Urol. 2008; 180: 13737.
  • 139
    Messing EM, Stamey TA. Interstitial cystitis: Early diagnosis, pathology, and treatment. Urology 1978; 12: 38192.
  • 140
    Driscoll A, Teichman JM. How do patients with interstitial cystitis present? J. Urol. 2001; 166: 211820.
  • 141
    Stanford EJ, Mattox TF, Parsons JK, McMurphy C. Prevalence of benign microscopic hematuria among women with interstitial cystitis: implications for evaluation of genitourinary malignancy. Urology 2006; 67: 9469.
  • 142
    Gomes CM, Sanchez-Ortiz RF, Harris C, Wein AJ, Rovner ES. Significance of hematuria in patients with interstitial cystitis: review of radiographic and endoscopic findings. Urology 2001; 57: 2625.
  • 143
    Awad SA, MacDiarmid S, Gajewski JB, Gupta R. Idiopathic reduced bladder storage versus interstitial cystitis. J. Urol. 1992; 148: 140912.
  • 144
    Al-Hadithi H, Tincello DG, Vince GS, Richmond DH. Leukocyte populations in interstitial cystitis and idiopathic reduced bladder storage. Urology 2002; 59: 8515.
  • 145
    Mukerji G, Waters J, Chessell IP, Bountra C, Agarwal SK, Anand P. Pain during ice water test distinguishes clinical bladder hypersensitivity from overactivity disorders. BMC Urol. 2006; 6: 31.
  • 146
    Braunstein R, Shapiro E, Kaye J, Moldwin R. The role of cystoscopy in the diagnosis of Hunner's ulcer disease. J. Urol. 2008; 180: 13836.
  • 147
    Lamale LM, Lutgendorf SK, Hoffman AN, Kreder KJ. Symptoms and cystoscopic findings in patients with untreated interstitial cystitis. Urology 2006; 67: 2425.
  • 148
    Ueda T, Nakagawa M, Okamura M, Tanoue H, Yoshida H, Yoshimura N. New cystoscopic diagnosis for interstitial cystitis/painful bladder syndrome using narrow-band imaging system. Int. J. Urol. 2008; 15: 103943.
  • 149
    Fall M, Aldenborg F, Johansson S, Peeker R. Clinical characteristics support that interstitial cystitis is a heterogeneous syndrome. Urology 2001; 57: 12930.
  • 150
    Logadottir YR, Ehren I, Fall M, Wiklund NP, Peeker R, Hanno PM. Intravesical nitric oxide production discriminates between classic and nonulcer interstitial cystitis. J. Urol. 2004; 171: 114850; discussion 50–1.
  • 151
    Messing E, Pauk D, Schaeffer A et al. Associations among cystoscopic findings and symptoms and physical examination findings in women enrolled in the Interstitial Cystitis Data Base (ICDB) Study. Urology 1997; 49: 815.
  • 152
    Mattila J. Vascular immunopathology in interstitial cystitis. Clin. Immunol. Immunopathol. 1982; 23: 64855.
  • 153
    Gillespie L, Said J, Sostrin S, Kleiwer K. Immunofluorescent and histochemical staining confirm the identification of the many diseases called interstitial cystitis. Br. J. Urol. 1990; 66: 26573.
  • 154
    Lynes WL, Flynn SD, Shortliffe LD, Stamey TA. The histology of interstitial cystitis. Am. J. Surg. Pathol. 1990; 14: 96976.
  • 155
    Rosamilia A, Igawa Y, Higashi S. Pathology of interstitial cystitis. Int. J. Urol. 2003; 10: (Suppl): S1115.
  • 156
    Parsons CL, Greenberger M, Gabal L, Bidair M, Barme G. The role of urinary potassium in the pathogenesis and diagnosis of interstitial cystitis. J. Urol. 1998; 159: 18626; discussion 1866–7.
  • 157
    Chambers GK, Fenster H. Re: the role of urinary potassium in the pathogenesis and diagnosis of interstitial cystitis. J. Urol. 1999; 161: 15812.
  • 158
    Gregoire M, Liandier F, Naud A, Lacombe L, Fradet Y. Does the potassium stimulation test predict cystometric, cystoscopic outcome in interstitial cystitis? J. Urol. 2002; 168: 5567.
  • 159
    Philip J, Willmott S, Irwin P. Interstitial cystitis versus detrusor overactivity: a comparative, randomized, controlled study of cystometry using saline and 0.3 M potassium chloride. J. Urol. 2006; 175: 56670; discussion 570–1.
  • 160
    Sairanen J, Tammela TL, Leppilahti M, Onali M, Forsell T, Ruutu M. Potassium sensitivity test (PST) as a measurement of treatment efficacy of painful bladder syndrome/interstitial cystitis: a prospective study with cyclosporine A and pentosan polysulfate sodium. Neurourol. Urodyn. 2007; 26: 26770.
  • 161
    Philip J, Willmott S, Owen D, Samsudin C, Irwin PP. A double-blind, randomized controlled trial of cystometry using saline versus 0.3 M potassium chloride infusion in women with overactive bladder syndrome. Neurourol. Urodyn. 2007; 26: 11014.
  • 162
    Keay SK, Szekely Z, Conrads TP et al. An antiproliferative factor from interstitial cystitis patients is a frizzled 8 protein-related sialoglycopeptide. Proc. Natl Acad. Sci USA 2004; 101: 118038.
  • 163
    Keay S, Zhang CO, Chai T et al. Antiproliferative factor, heparin-binding epidermal growth factor-like growth factor, and epidermal growth factor in men with interstitial cystitis versus chronic pelvic pain syndrome. Urology 2004; 63: 226.
  • 164
    Erickson DR, Kunselman AR, Bentley CM et al. Changes in urine markers and symptoms after bladder distention for interstitial cystitis. J. Urol. 2007; 177: 55660.
  • 165
    Sun Y, Chen M, Lowentritt BH et al. EGF and HB-EGF modulate inward potassium current in human bladder urothelial cells from normal and interstitial cystitis patients. Am. J. Physiol. Cell Physiol. 2007; 292: C10614.
  • 166
    Hosseini A, Ehren I, Wiklund NP. Nitric oxide as an objective marker for evaluation of treatment response in patients with classic interstitial cystitis. J. Urol. 2004; 172: 22615.
  • 167
    Lamale LM, Lutgendorf SK, Zimmerman MB, Kreder KJ. Interleukin-6, histamine, and methylhistamine as diagnostic markers for interstitial cystitis. Urology 2006; 68: 7026.
  • 168
    Canter MP, Graham CA, Heit MH et al. Proteomic techniques identify urine proteins that differentiate patients with interstitial cystitis from asymptomatic control subjects. Am. J. Obstet. Gynecol. 2008; 198: 553 e1–6.
  • 169
    Kuromitsu S, Yokota H, Hiramoto M, Morita S, Mita H, Yamada T. Increased concentration of neutrophil elastase in urine from patients with interstitial cystitis. Scand. J. Urol. Nephrol. 2008; 17.
  • 170
    Erickson DR, Tomaszewski JE, Kunselman AR et al. Urine markers do not predict biopsy findings or presence of bladder ulcers in interstitial cystitis/painful bladder syndrome. J. Urol. 2008; 179: 18506.
  • 171
    Fall M, Oberpenning F, Peeker R. Treatment of bladder pain syndrome/interstitial cystitis 2008: can we make evidence-based decisions? Eur. Urol. 2008; 54: 6575.
  • 172
    Chaiken DC, Blaivas JG, Blaivas ST. Behavioral therapy for the treatment of refractory interstitial cystitis. J. Urol. 1993; 149: 14458.
  • 173
    Parsons CL, Koprowski PF. Interstitial cystitis: successful management by increasing urinary voiding intervals. Urology 1991; 37: 20712.
  • 174
    Koziol JA, Clark DC, Gittes RF, Tan EM. The natural history of interstitial cystitis: a survey of 374 patients. J. Urol. 1993; 149: 4659.
  • 175
    McCormick N. Psychological Aspects of Interstitial Cystitis, in Sant G: Interstitial Cystitis. Lippincott-Raven, Philadelphia, PA, 1997; 1932003.
  • 176
    Webster DC, Brennan T. Self-care effectiveness and health outcomes in women with interstitial cystitis: implications for mental health clinicians. Iss. Ment. Health Nurs. 1998; 19: 495519.
  • 177
    Carrico DJ, Peters KM, Diokno AC. Guided imagery for women with interstitial cystitis: results of a prospective, randomized controlled pilot study. J. Altern. Complement. Med. 2008; 14: 5360.
  • 178
    Whitmore KE. Self-care regimens for patients with interstitial cystitis. Urol. Clin. North Am. 1994; 21: 12130.
  • 179
    Chung MK. Interstitial cystitis in persistent posthysterectomy chronic pelvic pain. JSLS 2004; 8: 32933.
  • 180
    Nickel JC. Interstitial cystitis. Etiology, diagnosis, and treatment. Can. Fam. Physician 2000; 46: 24304, 2437–40.
  • 181
    Gillespie L. Metabolic appraisal of the effects of dietary modification on hypersensitive bladder symptoms. Br. J. Urol. 1993; 72: 2937.
  • 182
    Moldwin RM, Sant GR. Interstitial cystitis: a pathophysiology and treatment update. Clin. Obstet. Gynecol. 2002; 45: 25972.
  • 183
    Shorter B, Lesser M, Moldwin RM, Kushner L. Effect of comestibles on symptoms of interstitial cystitis. J. Urol. 2007; 178: 14552.
  • 184
    Webster DC, Brennan T. Self-care strategies used for acute attack of interstitial cystitis. Urol. Nurs. 1995; 15: 8693.
  • 185
    Webster DC, Brennan T. Use and effectiveness of physical self-care strategies for interstitial cystitis. Nurse Pract. 1994; 19: 5561.
  • 186
    Bade JJ, Peeters JM, Mensink HJ. Is the diet of patients with interstitial cystitis related to their disease? Eur. Urol. 1997; 32: 17983.
  • 187
    Koziol JA. Epidemiology of interstitial cystitis. Urol. Clin. North Am. 1994; 21: 720.
  • 188
    Erickson DR, Davies MF. Interstitial cystitis. Int. Urogynecol. J. Pelvic Floor Dysfunct. 1998; 9: 17483.
  • 189
    Mendelowitz F, Moldwin R. Complementary approaches in the management of interstitial cystitis. In: SantG (ed.). Interstitial Cystitis. Lippincott-Raven, Philadelphia, PA, 1997; 2359.
  • 190
    Lukban J, Whitmore K, Kellogg-Spadt S, Bologna R, Lesher A, Fletcher E. The effect of manual physical therapy in patients diagnosed with interstitial cystitis, high-tone pelvic floor dysfunction, and sacroiliac dysfunction. Urology 2001; 57: 1212.
  • 191
    Holzberg A, Kellog-Spadt S, Lukban J, Whitmore K. Evaluation of transvaginal theile massage as a therapeutic intervention for women with interstitial cystitis. Urology 2001; 57: 120.
  • 192
    Weiss JM. Pelvic floor myofascial trigger points: manual therapy for interstitial cystitis and the urgency-frequency syndrome. J. Urol. 2001; 166: 222631.
  • 193
    Markwell SJ. Physical therapy management of pelvi/perineal and perianal pain syndromes. World J. Urol. 2001; 19: 1949.
  • 194
    Meadows E. Treatments for patients with pelvic pain. Urol. Nurs. 1999; 19: 335.
  • 195
    Lukban JC, Whitmore KE. Pelvic floor muscle re-education treatment of the overactive bladder and painful bladder syndrome. Clin. Obstet. Gynecol. 2002; 45: 27385.
  • 196
    Barrington JW, Stephenson TP. Pentosanpolysulphate for interstitial cystitis. Int. Urogynecol. J. Pelvic Floor Dysfunct. 1997; 8: 2935.
  • 197
    Parsons CL, Schmidt JD, Pollen JJ. Successful treatment of interstitial cystitis with sodium pentosanpolysulfate. J. Urol. 1983; 130: 513.
  • 198
    Fritjofsson A, Fall M, Juhlin R, Persson BE, Ruutu M. Treatment of ulcer and nonulcer interstitial cystitis with sodium pentosanpolysulfate: a multicenter trial. J. Urol. 1987; 138: 50812.
  • 199
    Holm-Bentzen M, Jacobsen F, Nerstrom B et al. A prospective double-blind clinically controlled multicenter trial of sodium pentosanpolysulfate in the treatment of interstitial cystitis and related painful bladder disease. J. Urol. 1987; 138: 5037.
  • 200
    Mulholland SG, Hanno P, Parsons CL, Sant GR, Staskin DR. Pentosan polysulfate sodium for therapy of interstitial cystitis. A double-blind placebo-controlled clinical study. Urology 1990; 35: 5528.
  • 201
    Parsons CL, Benson G, Childs SJ, Hanno P, Sant GR, Webster G. A quantitatively controlled method to study prospectively interstitial cystitis and demonstrate the efficacy of pentosanpolysulfate. J. Urol. 1993; 150: 8458.
  • 202
    Nickel JC, Barkin J, Forrest J et al. Randomized, double-blind, dose-ranging study of pentosan polysulfate sodium for interstitial cystitis. Urology 2005; 65: 6548.
  • 203
    Nickel JC, Kaufman DM, Zhang HF, Wan GJ, Sand PK. Time to initiation of pentosan polysulfate sodium treatment after interstitial cystitis diagnosis: effect on symptom improvement. Urology 2008; 71: 5761.
  • 204
    Hanno PM, Wein AJ. Medical treatment of interstitial cystitis (other than Rimso-50/Elmiron). Urology 1987; 29: 226.
  • 205
    Hanno PM, Wein AJ. Conservative therapy of interstitial cystitis. Semin. Urol. 1991; 9: 1437.
  • 206
    Pranikoff K, Constantino G. The use of amitriptyline in patients with urinary frequency and pain. Urology 1998; 51: 17981.
  • 207
    Kirkemo A, Miles B, Peters J. Use of amitriptyline in interstitial cystitis. J. Urol. 1990; 143: 279A.
  • 208
    Van Ophoven A, Pokupic S, Heinecke A, Hertle L. A prospective, randomized, placebo controlled, double-blind study of amitriptyline for the treatment of interstitial cystitis. J. Urol. 2004; 172: 5336.
  • 209
    Van Ophoven A, Hertle L. Long-term results of amitriptyline treatment for interstitial cystitis. J. Urol. 2005; 174: 183740.
  • 210
    Nishijima S, Sugaya K, Yamada T, Miyazato M, Ogawa Y. Efficacy of tricyclic antidepressant is associated with beta2-adrenoceptor genotype in patients with interstitial cystitis. Biomed. Res. 2006; 27: 1637.
  • 211
    Minogiannis P, El-Mansoury M, Betances JA, Sant GR, Theoharides TC. Hydroxyzine inhibits neurogenic bladder mast cell activation. Int. J. Immunopharmacol. 1998; 20: 55363.
  • 212
    Simmons JL, Bunce PL. On the use of an antihistamine in the treatment of interstitial cystitis. Am. Surg. 1958; 24: 6647.
  • 213
    Simmons J. Interstitial cystitis: an explanation for the beneficial effect of an antihistamine. J. Urol. 1961; 85: 14955.
  • 214
    Theoharides TC. Hydroxyzine for interstitial cystitis. J. Allergy Clin. Immunol. 1993; 91: 6867.
  • 215
    Theoharides TC. Hydroxyzine in the treatment of interstitial cystitis. Urol. Clin. North Am. 1994; 21: 11319.
  • 216
    Sant GR, Propert KJ, Hanno PM et al. A pilot clinical trial of oral pentosan polysulfate and oral hydroxyzine in patients with interstitial cystitis. J. Urol. 2003; 170: 81015.
  • 217
    Ueda T, Tamaki M, Ogawa O, Yamauchi T, Yoshimura N. Improvement of interstitial cystitis symptoms and problems that developed during treatment with oral IPD-1151T. J. Urol. 2000; 164: 191720.
  • 218
    Boucher W, Kempuraj D, Cao J, Papaliodis D, Theoharides TC. Intravesical suplatast tosilate (IPD-1151T) inhibits experimental bladder inflammation. J. Urol. 2007; 177: 118690.
  • 219
    Kirimoto T, Nakano K, Irimura K et al. Beneficial effects of suplatast tosilate (IPD-1151T) in a rat cystitis model induced by intravesical hydrochloric acid. BJU Int. 2007; 100: 9359.
  • 220
    Forsell T, Ruutu M, Isoniemi H, Ahonen J, Alfthan O. Cyclosporine in severe interstitial cystitis. J. Urol. 1996; 155: 15913.
  • 221
    Sairanen J, Forsell T, Ruutu M. Long-term outcome of patients with interstitial cystitis treated with low dose cyclosporine A. J. Urol. 2004; 171: 213841.
  • 222
    Sairanen J, Tammela TL, Leppilahti M et al. Cyclosporine A and pentosan polysulfate sodium for the treatment of interstitial cystitis: a randomized comparative study. J. Urol. 2005; 174: 22358.
  • 223
    Sairanen J, Hotakainen K, Tammela TL, Stenman UH, Ruutu M. Urinary epidermal growth factor and interleukin-6 levels in patients with painful bladder syndrome/interstitial cystitis treated with cyclosporine or pentosan polysulfate sodium. Urology 2008; 71: 6303.
  • 224
    Badenoch AW. Chronic interstitial cystitis. Br. J. Urol. 1971; 43: 71821.
  • 225
    Soucy F, Gregoire M. Efficacy of prednisone for severe refractory ulcerative interstitial cystitis. J. Urol. 2005; 173: 8413; discussion 843.
  • 226
    Seshadri P, Emerson L, Morales A. Cimetidine in the treatment of interstitial cystitis. Urology 1994; 44: 61416.
  • 227
    Lewi H. Cimetidine in treatment of interstitial cystitis. Urology 1995; 45: 1088.
  • 228
    Lewi H. Medical therapy in interstitial cystitis: the Essex experience. Urology 2001; 57: 120.
  • 229
    Thilagarajah R, Witherow RO, Walker MM. Oral cimetidine gives effective symptom relief in painful bladder disease: a prospective, randomized, double-blind placebo-controlled trial. BJU Int. 2001; 87: 20712.
  • 230
    Warren JW, Horne LM, Hebel JR, Marvel RP, Keay SK, Chai TC. Pilot study of sequential oral antibiotics for the treatment of interstitial cystitis. J. Urol. 2000; 163: 16858.
  • 231
    Smith SD, Wheeler MA, Foster HE Jr, Weiss RM. Improvement in interstitial cystitis symptom scores during treatment with oral L-arginine. J. Urol. 1997; 158: 7038.
  • 232
    Ehren I, Lundberg JO, Adolfsson J, Wiklund NP. Effects of L-arginine treatment on symptoms and bladder nitric oxide levels in patients with interstitial cystitis. Urology 1998; 52: 10269.
  • 233
    Korting GE, Smith SD, Wheeler MA, Weiss RM, Foster HE Jr. A randomized double-blind trial of oral L-arginine for treatment of interstitial cystitis. J. Urol. 1999; 161: 55865.
  • 234
    Cartledge JJ, Davies AM, Eardley I. A randomized double-blind placebo-controlled crossover trial of the efficacy of L-arginine in the treatment of interstitial cystitis. BJU Int. 2000; 85: 4216.
  • 235
    Birder LA, Kanai AJ, De Groat WC. DMSO: effect on bladder afferent neurons and nitric oxide release. J. Urol. 1997; 158: 198995.
  • 236
    Peeker R, Haghsheno MA, Holmang S, Fall M. Intravesical bacillus Calmette-Guerin and dimethyl sulfoxide for treatment of classic and nonulcer interstitial cystitis: a prospective, randomized double-blind study. J. Urol. 2000; 164: 191215; discussion 1915–16.
  • 237
    Perez-Marrero R, Emerson LE, Feltis JT. A controlled study of dimethyl sulfoxide in interstitial cystitis. J. Urol. 1988; 140: 369.
  • 238
    Ruiz JL, Alonso M, Moreno B, Server G, Osca JM, Jimenez JF. Dimethyl sulfoxide in the treatment of interstitial cystitis. Actas Urol. Esp. 1991; 15: 35760.
  • 239
    Fowler JE Jr. Prospective study of intravesical dimethyl sulfoxide in treatment of suspected early interstitial cystitis. Urology 1981; 18: 216.
  • 240
    Rossberger J, Fall M, Peeker R. Critical appraisal of dimethyl sulfoxide treatment for interstitial cystitis: discomfort, side-effects and treatment outcome. Scand. J. Urol. Nephrol. 2005; 39: 737.
  • 241
    Sant GR. Intravesical 50% dimethyl sulfoxide (Rimso-50) in treatment of interstitial cystitis. Urology 1987; 29: 1721.
  • 242
    Parsons CL, Housley T, Schmidt JD, Lebow D. Treatment of interstitial cystitis with intravesical heparin. Br. J. Urol. 1994; 73: 5047.
  • 243
    Kuo HC. Urodynamic results of intravesical heparin therapy for women with frequency urgency syndrome and interstitial cystitis. J. Formos. Med. Assoc. 2001; 100: 30914.
  • 244
    Welk BK, Teichman JM. Dyspareunia response in patients with interstitial cystitis treated with intravesical lidocaine, bicarbonate, and heparin. Urology 2008; 71: 6770.
  • 245
    Parsons CL. Successful downregulation of bladder sensory nerves with combination of heparin and alkalinized lidocaine in patients with interstitial cystitis. Urology 2005; 65: 458.
  • 246
    Leppilahti M, Hellstrom P, Tammela TL. Effect of diagnostic hydrodistension and four intravesical hyaluronic acid instillations on bladder ICAM-1 intensity and association of ICAM-1 intensity with clinical response in patients with interstitial cystitis. Urology 2002; 60: 4651.
  • 247
    Porru D, Campus G, Tudino D et al. Results of treatment of refractory interstitial cystitis with intravesical hyaluronic acid. Urol. Int. 1997; 59: 269.
  • 248
    Morales A, Emerson L, Nickel JC. Intravesical hyaluronic acid in the treatment of refractory interstitial cystitis. Urology 1997; 49: 11113.
  • 249
    Morales A, Emerson L, Nickel JC, Lundie M. Intravesical hyaluronic acid in the treatment of refractory interstitial cystitis. J. Urol. 1996; 156: 458.
  • 250
    Kallestrup EB, Jorgensen SS, Nordling J, Hald T. Treatment of interstitial cystitis with Cystistat: a hyaluronic acid product. Scand. J. Urol. Nephrol. 2005; 39: 1437.
  • 251
    Iavazzo C, Athanasiou S, Pitsouni E, Falagas ME. Hyaluronic acid: an effective alternative treatment of interstitial cystitis, recurrent urinary tract infections, and hemorrhagic cystitis? Eur. Urol. 2007; 51: 153440; discussion 1540–1.
  • 252
    Riedl CR, Engelhardt PF, Daha KL, Morakis N, Pfluger H. Hyaluronan treatment of interstitial cystitis/painful bladder syndrome. Int. Urogynecol. J. Pelvic Floor Dysfunct. 2008; 19: 71721.
  • 253
    Steinhoff G, Ittah B, Rowan S. The efficacy of chondroitin sulfate 0.2% in treating interstitial cystitis. Can. J. Urol. 2002; 9: 14548.
  • 254
    Nickel JC, Egerdie B, Downey J et al. A real-life multicentre clinical practice study to evaluate the efficacy and safety of intravesical chondroitin sulphate for the treatment of interstitial cystitis. BJU Int. 2009; 103: 5660.
  • 255
    Nordling J, Van Ophoven A. Intravesical glycosaminoglycan replenishment with chondroitin sulphate in chronic forms of cystitis. A multi-national, multi-centre, prospective observational clinical trial. Arzneimittelforschung 2008; 58: 32835.
  • 256
    Cervigni M, Natale F, Nasta L, Padoa A, Voi RL, Porru D. A combined intravesical therapy with hyaluronic acid and chondroitin for refractory painful bladder syndrome/interstitial cystitis. Int. Urogynecol. J. Pelvic Floor Dysfunct. 2008; 19: 9437.
  • 257
    Davis EL, El Khoudary SR, Talbott EO, Davis J, Regan LJ. Safety and efficacy of the use of intravesical and oral pentosan polysulfate sodium for interstitial cystitis: a randomized double-blind clinical trial. J. Urol. 2008; 179: 17785.
  • 258
    Davis EL, El Khoudary SR, Talbott EO, Davis J, Regan LJ. Safety and efficacy of the use of intravesical and oral pentosan polysulfate sodium for interstitial cystitis: a randomized double-blind clinical trial. J. Urol. 2008; 179: 17785.
  • 259
    Barbalias GA, Liatsikos EN, Athanasopoulos A, Nikiforidis G. Interstitial cystitis: bladder training with intravesical oxybutynin. J. Urol. 2000; 163: 181822.
  • 260
    Riedl CR, Knoll M, Plas E, Pfluger H. Electromotive drug administration and hydrodistention for the treatment of interstitial cystitis. J. Endourol. 1998; 12: 26972.
  • 261
    Rosamilia A, Dwyer PL, Gibson J. Electromotive drug administration of lidocaine and dexamethasone followed by cystodistension in women with interstitial cystitis. Int. Urogynecol. J. Pelvic Floor Dysfunct. 1997; 8: 1425.
  • 262
    Riedl CR, Knoll M, Plas E, Stephen RL, Pfluger H. Intravesical electromotive drug administration for the treatment of non-infectious chronic cystitis. Int. Urogynecol. J. Pelvic Floor Dysfunct. 1997; 8: 1347.
  • 263
    Gurpinar T, Wong HY, Griffith DP. Electromotive administration of intravesical lidocaine in patients with interstitial cystitis. J. Endourol. 1996; 10: 4437.
  • 264
    Fagerli J, Fraser MO, DeGroat WC et al. Intravesical capsaicin for the treatment of interstitial cystitis: a pilot study. Can. J. Urol. 1999; 6: 73744.
  • 265
    Lazzeri M, Spinelli M, Beneforti P, Malaguti S, Giardiello G, Turini D. Intravesical infusion of resiniferatoxin by a temporary in situ drug delivery system to treat interstitial cystitis: a pilot study. Eur. Urol. 2004; 45: 98102.
  • 266
    Takahashi S, Yanase M, Inoue R et al. Intravesical instillation of resiniferatoxin for the patients with interstitial cystitis. Hinyokika Kiyo 2006; 52: 91113.
  • 267
    Peng CH, Kuo HC. Multiple intravesical instillations of low-dose resiniferatoxin in the treatment of refractory interstitial cystitis. Urol. Int. 2007; 78: 7881.
  • 268
    Payne CK, Mosbaugh PG, Forrest JB et al. Intravesical resiniferatoxin for the treatment of interstitial cystitis: a randomized, double-blind, placebo controlled trial. J. Urol. 2005; 173: 15904.
  • 269
    Chen TY, Corcos J, Camel M, Ponsot Y, Tu le M. Prospective, randomized, double-blind study of safety and tolerability of intravesical resiniferatoxin (RTX) in interstitial cystitis (IC). Int. Urogynecol. J. Pelvic Floor Dysfunct. 2005; 16: 2937.
  • 270
    Chuang YC, Yoshimura N, Huang CC, Chiang PH, Chancellor MB. Intravesical botulinum toxin a administration produces analgesia against acetic acid induced bladder pain responses in rats. J. Urol. 2004; 172: 152932.
  • 271
    Lucioni A, Bales GT, Lotan TL, McGehee DS, Cook SP, Rapp DE. Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammation. BJU Int. 2008; 101: 36670.
  • 272
    Smith CP, Radziszewski P, Borkowski A, Somogyi GT, Boone TB, Chancellor MB. Botulinum toxin a has antinociceptive effects in treating interstitial cystitis. Urology 2004; 64: 8715; discussion 875.
  • 273
    Giannantoni A, Costantini E, Di Stasi SM, Tascini MC, Bini V, Porena M. Botulinum A toxin intravesical injections in the treatment of painful bladder syndrome: a pilot study. Eur. Urol. 2006; 49: 7049.
  • 274
    Liu HT, Kuo HC. Intravesical botulinum toxin A injections plus hydrodistension can reduce nerve growth factor production and control bladder pain in interstitial cystitis. Urology 2007; 70: 4638.
  • 275
    Giannantoni A, Porena M, Costantini E, Zucchi A, Mearini L, Mearini E. Botulinum A toxin intravesical injection in patients with painful bladder syndrome: 1-year follow up. J. Urol. 2008; 179: 10314.
  • 276
    Aghamir SM, Mohseni MG, Arasteh S. Intravesical Bacillus Calmette-Guerin for treatment of refractory interstitial cystitis. Urol. J. 2007; 4: 1823.
  • 277
    Peters K, Diokno A, Steinert B et al. The efficacy of intravesical Tice strain bacillus Calmette-Guerin in the treatment of interstitial cystitis: a double-blind, prospective, placebo controlled trial. J. Urol. 1997; 157: 20904.
  • 278
    Peters KM, Diokno AC, Steinert BW, Gonzalez JA. The efficacy of intravesical bacillus Calmette-Guerin in the treatment of interstitial cystitis: long-term follow up. J. Urol. 1998; 159: 14836; discussion 1486–7.
  • 279
    Zeidman EJ, Helfrick B, Pollard C, Thompson IM. Bacillus Calmette-Guerin immunotherapy for refractory interstitial cystitis. Urology 1994; 43: 1214.
  • 280
    Mayer R, Propert KJ, Peters KM et al. A randomized controlled trial of intravesical bacillus calmette-guerin for treatment refractory interstitial cystitis. J. Urol. 2005; 173: 118691.
  • 281
    Propert KJ, Mayer R, Nickel JC et al. Did patients with interstitial cystitis who failed to respond to initial treatment with bacillus Calmette-Guerin or placebo in a randomized clinical trial benefit from a second course of open label bacillus Calmette-Guerin? J. Urol. 2007; 178: 88690.
  • 282
    Bade JJ, Rijcken B, Mensink HJ. Interstitial cystitis in The Netherlands: prevalence, diagnostic criteria and therapeutic preferences. J. Urol. 1995; 154: 20357; discussion 2037–8.
  • 283
    Rovner E, Propert KJ, Brensinger C et al. Treatments used in women with interstitial cystitis: the interstitial cystitis data base (ICDB) study experience. The Interstitial Cystitis Data Base Study Group. Urology 2000; 56: 9405.
  • 284
    Bumpus HJ. Interstitial cystitis: its treatment by over-distention of the bladder. Med. Clin. North Am. 1930; 13: 14958.
  • 285
    Yamada T, Murayama T, Andoh M. Adjuvant hydrodistension under epidural anesthesia for interstitial cystitis. Int. J. Urol. 2003; 10: 4638; discussion 469.
  • 286
    Dunn M, Ramsden PD, Roberts JB, Smith JC, Smith PJ. Interstitial cystitis, treated by prolonged bladder distension. Br. J. Urol. 1977; 49: 6415.
  • 287
    Glemain P, Riviere C, Lenormand L, Karam G, Bouchot O, Buzelin JM. Prolonged hydrodistention of the bladder for symptomatic treatment of interstitial cystitis: efficacy at 6 months and 1 year. Eur. Urol. 2002; 41: 7984.
  • 288
    Tomoe H, Kobayashi H, Nakazawa H, Toma H. The efficacy of hydrodistension of the bladder for interstitial cystitis. J. Interst. Cyst. 2004; 2: 2431.
  • 289
    Gosling JA, Dixon JS, Dunn M. The structure of the rabbit urinary bladder after experimental distension. Invest. Urol. 1977; 14: 3869.
  • 290
    Taub HC, Stein M. Bladder distention therapy for symptomatic relief of frequency and urgency: a ten-year review. Urology 1994; 43: 369.
  • 291
    Higson RH, Smith JC, Whelan P. Bladder rupture: an acceptable complication of distension therapy? Br. J. Urol. 1978; 50: 52934.
  • 292
    Zabihi N, Allee T, Maher MG et al. Bladder necrosis following hydrodistention in patients with interstitial cystitis. J. Urol. 2007; 177: 14952; discussion 152.
  • 293
    Uchida E, Ishimaru R, Mukubo Y, Tomoe H, Nakazawa H, Kawamata M. Patient satisfaction with anesthesia for hydrodistension during perioperative period. Nippon Hinyokika Gakkai Zasshi 2005; 96: 274.
  • 294
    Fall M. Conservative management of chronic interstitial cystitis: transcutaneous electrical nerve stimulation and transurethral resection. J. Urol. 1985; 133: 7748.
  • 295
    Fall M, Lindstrom S. Transcutaneous electrical nerve stimulation in classic and nonulcer interstitial cystitis. Urol. Clin. North Am. 1994; 21: 1319.
  • 296
    Geirsson G, Wang YH, Lindstrom S, Fall M. Traditional acupuncture and electrical stimulation of the posterior tibial nerve. A trial in chronic interstitial cystitis. Scand. J. Urol. Nephrol. 1993; 27: 6770.
  • 297
    Bristow SE, Hasan ST, Neal DE. TENS: a treatment option for bladder dysfunction. Int. Urogynecol. J. Pelvic Floor Dysfunct. 1996; 7: 18590.
  • 298
    Zhao J, Bai J, Zhou Y, Qi G, Du L. Posterior tibial nerve stimulation twice a week in patients with interstitial cystitis. Urology 2008; 71: 10804.
  • 299
    Whitmore KE, Payne CK, Diokno AC, Lukban JC. Sacral neuromodulation in patients with interstitial cystitis: a multicenter clinical trial. Int. Urogynecol. J. Pelvic Floor Dysfunct. 2003; 14: 3058; discussion 308–9.
  • 300
    Peters KM. Neuromodulation for the treatment of refractory interstitial cystitis. Rev. Urol. 2002; 4 (Suppl 1): S3643.
  • 301
    Maher CF, Carey MP, Dwyer PL, Schluter PL. Percutaneous sacral nerve root neuromodulation for intractable interstitial cystitis. J. Urol. 2001; 165: 8846.
  • 302
    Comiter CV. Sacral neuromodulation for the symptomatic treatment of refractory interstitial cystitis: a prospective study. J. Urol. 2003; 169: 136973.
  • 303
    Zermann DH, Weirich T, Wunderlich H, Reichelt O, Schubert J. Sacral nerve stimulation for pain relief in interstitial cystitis. Urol. Int. 2000; 65: 1201.
  • 304
    Steinberg AC, Oyama IA, Whitmore KE. Bilateral S3 stimulator in patients with interstitial cystitis. Urology 2007; 69: 4413.
  • 305
    Peters KM, Feber KM, Bennett RC. A prospective, single-blind, randomized crossover trial of sacral vs pudendal nerve stimulation for interstitial cystitis. BJU Int. 2007; 100: 8359.
  • 306
    Chang PL. Urodynamic studies in acupuncture for women with frequency, urgency and dysuria. J. Urol. 1988; 140: 5636.
  • 307
    Chang PL, Wu CJ, Huang MH. Long-term outcome of acupuncture in women with frequency, urgency and dysuria. Am. J. Chin Med. 1993; 21: 2316.
  • 308
    O'Reilly BA, Dwyer PL, Hawthorne G et al. Transdermal posterior tibial nerve laser therapy is not effective in women with interstitial cystitis. J. Urol. 2004; 172: 18803.
  • 309
    Tanaka T, Kawashima H, Makino T, Kamikawa S, Kato N, Nakatani T. Hyperbaric oxygen therapy for interstitial cystitis resistant to conventional treatments. Int. J. Urol. 2007; 14: 5635.
  • 310
    Van Ophoven A, Rossbach G, Pajonk F, Hertle L. Safety and efficacy of hyperbaric oxygen therapy for the treatment of interstitial cystitis: a randomized, sham controlled, double-blind trial. J. Urol. 2006; 176: 14426.
  • 311
    Kerr WS Jr. Interstitial cystitis: treatment by transurethral resection. J. Urol. 1971; 105: 6646.
  • 312
    Peeker R, Aldenborg F, Fall M. Complete transurethral resection of ulcers in classic interstitial cystitis. Int. Urogynecol. J. Pelvic Floor Dysfunct. 2000; 11: 2905.
  • 313
    Greenberg E, Barnes R, Stewart S, Furnish T. Transurethral resection of Hunner's ulcer. J. Urol. 1974; 111: 7646.
  • 314
    Kaneko T, Fujita K, Homma Y. Clinical experience on 52 patients with interstitial cystitis. Nippon Hinyokika Gakkai Zasshi 2006; 97: 7716.
  • 315
    Shanberg AM, Baghdassarian R, Tansey LA. Treatment of interstitial cystitis with the neodymium-YAG laser. J. Urol. 1985; 134: 8858.
  • 316
    Shanberg AM, Malloy T. Treatment of interstitial cystitis with neodymium:YAG laser. Urology 1987; 29: 313.
  • 317
    Malloy TR, Shanberg AM. Laser therapy for interstitial cystitis. Urol. Clin. North Am. 1994; 21: 1414.
  • 318
    Rofeim O, Hom D, Freid RM, Moldwin RM. Use of the neodymium: YAG laser for interstitial cystitis: a prospective study. J. Urol. 2001; 166: 1346.
  • 319
    Van Ophoven A, Oberpenning F, Hertle L. Long-term results of trigone-preserving orthotopic substitution enterocystoplasty for interstitial cystitis. J. Urol. 2002; 167: 6037.
  • 320
    Irwin PP, Galloway NT. Surgical management of interstitial cystitis. Urol. Clin. North Am. 1994; 21: 14551.
  • 321
    Linn JF, Hohenfellner M, Roth S et al. Treatment of interstitial cystitis: comparison of subtrigonal and supratrigonal cystectomy combined with orthotopic bladder substitution. J. Urol. 1998; 159: 7748.
  • 322
    Kontturi MJ, Hellstrom PA, Tammela TL, Lukkarinen OA. Colocystoplasty for the treatment of severe interstitial cystitis. Urol. Int. 1991; 46: 504.
  • 323
    Nielsen KK, Kromann-Andersen B, Steven K, Hald T. Failure of combined supratrigonal cystectomy and Mainz ileocecocystoplasty in intractable interstitial cystitis: is histology and mast cell count a reliable predictor for the outcome of surgery? J. Urol. 1990; 144: 2558; discussion 258–9.
  • 324
    Peeker R, Aldenborg F, Fall M. The treatment of interstitial cystitis with supratrigonal cystectomy and ileocystoplasty: difference in outcome between classic and nonulcer disease. J. Urol. 1998; 159: 147982.
  • 325
    Rossberger J, Fall M, Jonsson O, Peeker R. Long-term results of reconstructive surgery in patients with bladder pain syndrome/interstitial cystitis: subtyping is imperative. Urology 2007; 70: 63842.
  • 326
    Nurse DE, Parry JR, Mundy AR. Problems in the surgical treatment of interstitial cystitis. Br. J. Urol. 1991; 68: 1534.
  • 327
    Chakravarti A, Ganta S, Somani B, Jones MA. Caecocystoplasty for intractable interstitial cystitis: long-term results. Eur. Urol. 2004; 46: 11417.
  • 328
    Gershbaum D, Moldwin R. Practice trends for the management of interstitial cystitis. Urology 2001; 57: 119.
  • 329
    Baskin LS, Tanagho EA. Pelvic pain without pelvic organs. J. Urol. 1992; 147: 6836.
  • 330
    Blaivas JG, Weiss JP, Desai P, Flisser AJ, Stember DS, Stahl PJ. Long-term follow up of augmentation enterocystoplasty and continent diversion in patients with benign disease. J. Urol. 2005; 173: 16314.
  • 331
    Elzawahri A, Bissada NK, Herchorn S et al. Urinary conduit formation using a retubularized bowel from continent urinary diversion or intestinal augmentations: ii. Does it have a role in patients with interstitial cystitis? J. Urol. 2004; 171: 155962.
  • 332
    Freiha FS, Faysal MH, Stamey TA. The surgical treatment of intractable interstitial cystitis. J. Urol. 1980; 123: 6324.
  • 333
    Propert KJ, Payne C, Kusek JW, Nyberg LM. Pitfalls in the design of clinical trials for interstitial cystitis. Urology 2002; 60: 7428.